學術研究成果/Publication
基本資料/Profiles
姓名/Name: 彭成元 性別/Gender:
英文姓名/
English Name:
Peng, Cheng-Yuan 英文縮寫/
Abbreviation:
CY Peng
任職單位/
Affiliation:
1.醫學院醫學系學士班內科學科(教授) / Department of Internal Medicine (Professor)
2.中國附醫內科部消化系(系主任) / Digestive Medicine (Director)
Email: cypeng@mail.cmuh.org.tw
研究專長/Fields of Specialty
1﹒ Molecular mechanisms of hepatocarcinogenesis
2﹒ Clinical hepatology
 
期刊論文/Journal Paper
(作者群,論文題目,期刊名稱,出版年月,卷號(期別):頁次起迄)
SCI論文 許偉帆(Wei-Fan Hsu)、陳春妃(Chuen-Fei Chen)、賴學洲(Lai, Hsueh-Chou)、蘇文邦(Wen-Pang Su)、林佳欣、莊伯恒(Po-Heng Chuang)、陳昇弘(Chen, Sheng-Hung)、陳浤燿(Chen, Ching-Hsiang)、王鴻偉(Hung-Wei Wang)、黃冠棠、彭成元(Peng, Cheng-Yuan)*,Trajectories of serum hepatitis B surface antigen kinetics in patients with chronic hepatitis B receiving long-term nucleos(t)ide analogue therapy,LIVER INTERNATIONAL,2018 Apr,38(4):627-635
SCI論文 陳昇弘(Chen, Sheng-Hung)、彭成元(Peng, Cheng-Yuan)*,Ultrasound-Based Liver Stiffness Surveillance in Patients Treated for Chronic Hepatitis B or C,Applied Sciences-Basel,2018 Apr,8(4):626-626
SCI論文 (Liu CJ)、(Chuang WL)、(Sheen IS)、(Wang HY)、(Chen CY)、(Tseng KC)、(Chang TT)、(Massetto B)、(Yang JC)、(Yun C)、(Knox SJ)、(Osinusi A)、(Camus G)、(Jiang D)、(Brainard DM)、(McHutchison JG)、(Hu TH)、(Hsu YC)、(Lo GH)、(Chu CJ)、(Chen JJ)、彭成元(Peng, Cheng-Yuan)、(Chien RN)、(Chen PJ)*,Efficacy of ledipasvir and sofosbuvir treatment of HCV infection in patients coinfected with HBV,GASTROENTEROLOGY,2018 Mar,154():989-997
SCI論文 (Hsu CW)、(Su WW)、(Lee CM)、彭成元(Peng, Cheng-Yuan)、(Chuang WL)、(Kao JH)、(Chu HC)、(Huang YH)、(Chien RN)*、(Liaw YF),Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B,JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION,2018 Feb,():
SCI論文 (Won Young Tak)*、(Shi-Ming Lin)、(Yijun Wang)、(Jiasheng Zheng)、(Aldo Vecchione)、(Soo Young Park)、(Min Hua Chen)、(Stephen Wong)、(Ruocai Xu)、彭成元(Peng, Cheng-Yuan)、(Yi-You Chiou)、(Guan-Tarn Huang)、(Jianqiang Cai)、(Basri Johan Jeet Abdullah)、(June Sung Lee)、(Jae Young Lee)、(Jong-Young Choi)、(Julieta Gopez-Cervantes)、(Morris Sherman)、(Richard S. Finn)、(Masao Omata)、(Michael O'Neal)、(Lukas Makris)、(Nicholas Borys 2)、(Ronnie Poon)、(Riccardo Lencioni),Phase III HEAT study adding lyso-thermosensitive liposomal doxorubicin to radiofrequency ablation in patients with unresectable hepatocellular carcinoma lesions,CLINICAL CANCER RESEARCH,2018 Jan,24(1):73-83
SCI論文 陳昇弘(Chen, Sheng-Hung)、賴學洲(Lai, Hsueh-Chou)、江宜平(Chiang, I-Ping)、蘇文邦(Wen-Pang Su)、林佳欣、高榮達(Kao, Jung-Ta)、莊伯恒(Po-Heng Chuang)、許偉帆(Wei-Fan Hsu)、王鴻偉(Hung-Wei Wang)、陳浤燿(Chen, Ching-Hsiang)、黃冠棠、彭成元(Peng, Cheng-Yuan)*,Changes in liver stiffness measurement using acoustic radiation force impulse elastography after antiviral therapy in patients with chronic hepatitis C,PLoS One,2018 Jan,13(1):e0190455-e0190455
SCI論文 (Kao JH)*、(Yu ML)、(Chen CY)、彭成元(Peng, Cheng-Yuan)、(Chen MY)、(Tang H)、(Chen Q)、(Wu JJ),Twelve-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study,JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY,2018 Jan,():
SCI論文 (Chen CH)、(Lee CM)、賴學洲(Lai, Hsueh-Chou)、(Hu TH)、蘇文邦(Wen-Pang Su)、(Lu SN)、林佳欣、(Hung CH)、(Wang JH)、(Lee MH)、彭成元(Peng, Cheng-Yuan)*,Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir,Oncotarget,2017 Sep,8(54):92431-9244
SCI論文 (Reddy KR)*、(Pol S)、(Thuluvath PJ)、(Kumada H)、(Toyota J)、(Chayama K)、(Levin J)、(Lawitz EJ)、(Gadano A)、(Ghesquiere W)、(Gerken G)、(Brunetto MR)、彭成元(Peng, Cheng-Yuan)、(Silva M)、(Strasser SI)、(Heo J)、(McPhee F)、(Liu Z)、(Yang R)、(Linaberry M)、(Noviello S),Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens,LIVER INTERNATIONAL,2017 Sep,():
SCI論文 朱家聲(Chia-Sheng Chu)、林則成(Che-Chen Lin)、彭成元(Peng, Cheng-Yuan)、莊伯恒(Po-Heng Chuang)、蘇文邦(Wen-Pang Su)、賴世偉(Lai, Shih-Wei)、陳宣如(Hsuan-Ju Chjen)、鍾季容(Chung, Chi-Jung)*、賴學洲(Lai, Hsueh-Chou)*,Does pyogenic liver abscess increase the risk of delayed-onset primary liver cancer? Evidence from a nationwide cohort study,MEDICINE,2017 Aug,96(34):e7785
SCI論文 (Mei-Hsuan Lee)*、(Chung-Feng Huang)、賴學洲(Hsueh-Chou Lai)、(Chun-Yen Lin)、(Chia-Yen Dia)、(Chun-Jen Liu)、(Jing-Houng Wang)、(Jee-Fu Huang)、蘇文邦(Wen-Pang Su)、(Hung-Chih Yang)、(Kwong-Ming Kee)、(Ming-Lun Yeh)、莊伯恒(Po-Heng Chuang)、Shih-Jer Hsu、(Ching-I Huang)、高榮達(Jung-Ta Kao)、(Chieh-Chang Chen)、陳昇弘(Sheng-Hung Chen)、(Wen-Juei Jeng)、(Hwai-I Yang)、(Yong Yuan)、(Sheng-Nan Lu)*、(I-Shyan Sheen)*、(Chen-Hua Liu)*、彭成元(Cheng-Yuan Peng)*、(Jia-Horng Kao)*、(Ming-Lung Yu)*、(Wan-Long Chuang)*、(Chien-Jen Chen)*,Clinical efficacy and post-treatment seromarkers associated with the risk of hepatocellular carcinoma among chronic hepatitis C patients,Scientific Reports,2017 Jun,7(1):3718-3718
SCI論文 王鴻偉(Hung-Wei Wang)、彭成元(Cheng-Yuan Peng)*、賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、林佳欣、莊伯恒(Po-Heng Chuang)、陳昇弘(Sheng-Hung Chen)、陳景祥(Ching-Hsiang Chen)、許偉帆(Wei-Fan Hsu)、黃冠棠,New noninvasive index for predicting liver fibrosis in Asian patients with chronic viral hepatitis,Scientific Reports,2017 Jun,7(1):3259
SCI論文 (Jia-Horng Kao)、(Ming-Lung Yu)、彭成元(Peng, Cheng-Yuan)、(Jeong Heo)、(Chi-Jen Chu)、(Ting-Tsung Chang)、(Youn-Jae Lee)、(Tsung-Hui Hu)、(Ki Tae Yoon)、(Seung Woon Paik)、(Young Suk Lim)、(Sang Hoon Ahn)、(Vasily Isakov)、(Fiona McPhee)、(Wenhua Hu)、(E Scott Swenson)、(Philip D Yin)、(Michelle Treitel)*,Daclatasvir/asunaprevir/beclabuvir(DCV-TRIO), all-oral, fixed-dose combination for patients with chronic HCV genotype 1,JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY,2017 May,():
SCI論文 (Ira M. Jacobson)*、(Eric Lawitz)、(Paul Y. Kwo)、(Christophe Hezode)、彭成元(Peng, Cheng-Yuan)、(AnitaY.M.Howe)、(Peggy Hwang)、(Janice Wahl)、(Michael Robertson)、(Eliav Barr)、(Barbara A. Haber),Safety and efficacy of elbasvir/grazoprevir in patients with hepatitis C virus infection and compensated cirrhosis: an integrated analysis,GASTROENTEROLOGY,2017 May,152():1372-1382
SCI論文 (Sandra Phillips)、(Sameer Mistry)、(Antonio Riva)、(Helen Cooksley)、(Tanya Hadzhiolova-Lebeau)、(Slava Plavova)、(Krum Katzarov)、(Marieta Simonova)、(Stephan Zeuzem)、(Clive Woffendin)、(Pei-Jer Chen)、彭成元(Peng, Cheng-Yuan)、(Ting-Tsung Chang)、(Stefan Lueth)、(Robert De Knegt)、(Moon-Seok Choi)、(Heiner Wedemeyer)、(Michael Dao)、(Chang-Wook Kim)、(Heng-Chen Chu)、(Megan Wind-Rotolo)、(Roger Williams)、(Elizabeth Cooney)、(Shilpa Chokshi1)*,Peg-interferon lambda treatment induces robust innate and adaptive immunity in chronic hepatitis B patients,Frontiers in Immunology,2017 May,8(621):
SCI論文 張倍禎(Chang, Jane Pei-Chen)、賴學洲(Lai, Hsueh-Chou)、楊惠婷(Yang, Hui-Ting)、蘇文邦(Wen-Pang Su)、彭成元(Peng, Cheng-Yuan)、(Piotr Ga?ecki)、(Anna Walczewska)、(Carmine M Pariante)、蘇冠賓(Su, Kuan-Pin)*,Polyunsaturated fatty acids levels and initial presentation of somatic symptoms induced by interferon-alpha therapy in patients with chronic hepatitis C viral infection,NUTRITIONAL NEUROSCIENCE,2017 May,20(5):291-296
SCI論文 彭成元(Cheng-Yuan Peng)*、賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、林佳欣、莊伯恒(Po-Heng Chuang)、陳昇弘(Sheng-Hung Chen)、陳景祥(Ching-Hsiang Chen),Early hepatitis B surface antigen decline predicts treatment response to entecavir in patients with chronic hepatitis B,Scientific Reports,2017 Feb,21(7):42879
SCI論文 (Tung-Hung Su)、(?Tsung-Hui Hu)、(Chi-Yi Chen)、(Yi-Hsiang Huang)、(Wan-Long Chuang)、(Chun-Che Lin)、(Chia-Chi Wang)、(Wei-Wen Su)、(Ming-Yao Chen)、彭成元(Cheng-Yuan Peng)、(Rong-Nan Chien)、(Yi-Wen Huang)、(Horng-Yuan Wang)、(Chih-Lin Lin)、(Sheng-Shun Yang)、(Tsung-Ming Chen)、(Lein-Ray Mo)、(Shih-Jer Hsu)、(Kuo-Chih Tseng)、(?Tsai-Yuan Hsieh)、(Fat-Moon Suk)、(Chi-Tan Hu)、(Ming-Jong Bair)、(Cheng-Chao Liang)、(Yung-Chao Lei)、(Tai-Chung Tseng)、(Chi-Ling Chen)、(Jia-Horng Kao)*,Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients,LIVER INTERNATIONAL,2016 Dec,36(12):1755-1764
SCI論文 賴宥良(Yo-Liang Lai)、郭于誠(Yu-Cheng, Kuo)、賴學洲(Hsueh-Chou Lai)、彭成元(Cheng-Yuan Peng)、王耀慶(Yao-Ching Wang)、梁基安(Liang, Ji-An)、陳尚文(Shang-Wen Chen)*,Early radiation-induced liver toxicities are associated with poor survival in patients with advanced hepatocellular carcinoma,Asia-Pacific Journal of Clinical Oncology,2016 Dec,12(4):437-443
SCI論文 (Gregory J. Dore)*、(Frederick Altice)、(Alain H. Litwin)、(Olav Dalgard)、(Edward J. Gane)、(Oren Shibolet)、(Anne Luetkemeyer)、(Ronald Nahass)、彭成元(Cheng-Yuan Peng)、(Brian Conway)、(Jason Grebely)、(Anita Y.M. Howe)、(Isaias N. Gendrano)、(Erluo Chen)、(Hsueh-Cheng Huang)、(Frank J. Dutko)、(David C. Nickle)、(Bach-Yen Nguyen)、(Janice Wahl)、(Eliav Barr)、(Michael N. Robertson)、(Heather L. Platt),Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial,ANNALS OF INTERNAL MEDICINE,2016 Nov,165(9):625-634
SCI論文 (Jia-Horng Kao)*、(Youn-Jae Lee)、(Jeong Heo)、(Sang-Hoon Ahn)、(Young-Suk Lim)、彭成元(Cheng-Yuan Peng)、(Ting-Tsung Chang)、(Anne Torbeyns)、(Eric Hughes)、(Ra?a Bhore)、(Stephanie Noviello),All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study,LIVER INTERNATIONAL,2016 Oct,36(10):1433-1441
SCI論文 (Paul Kwo)*、(Edward Gane)、彭成元(Cheng-Yuan Peng)、(Brian Pearlman)、(John M. Vierling)、(LawrenceSerfaty)、(Maria Buti)、(Stephen Shafran)、(Paul Stryszak)、(Li Lin)、(Jacqueline Gress)、(StuartBlack)、(Frank J. Dutko)、(Michael Robertson)、(Janice Wahl)、(Lisa Lupinacci)、(EliavBarr)、(Barbara Haber),Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection,GASTROENTEROLOGY,2016 Oct,S0016-5085(16):35170-35178
SCI論文 (Ding-Shinn Chen)*、(Yun-Fan Liaw)、(Chien-Jen Chen)、(Jaw-ChingWu)、(Wan-Long Chuang)、彭成元(Cheng-Yuan Peng)、(Rong-NanChien),Differences in hepatitis viral etiology of hepatocellular carcinoma in Taiwan and China,HEPATOLOGY,2016 Sep,64(3):1008-1009
SCI論文 蔡宗佑(Tsung-Yu Tsai)、(Che-Chen Lin)、彭成元(Cheng-Yuan Peng)、黃文信(Wen-Hsin Huang)、蘇文邦(Wen-Pang Su)、賴世偉(Shih-Wei Lai)、(Hsuan-Ju Chen)、賴學洲(Hsueh-Chou Lai)*,The Association between Biliary Tract Inflammation and Risk of Digestive System Cancers: A Population-Based Cohort Study,MEDICINE,2016 Aug,():
SCI論文 陳昇弘(Sheng-Hung Chen)、彭成元(Cheng-Yuan Peng)*、江宜平(I-Ping Chiang)、賴學洲(Hsueh-Chou Lai)、李瓊如(Chiung-Ju Lee)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao)、莊伯恒(Po-Heng Chuang),Comparison of collagen proportionate areas in liver fibrosis quantification between chronic hepatitis B and C.,MEDICINE,2016 Aug,95(35):e4736-e4736
SCI論文 (Jia-Horng Kao)、(Rong-Nan Chien)、(Ting-Tsung Chang)、彭成元(Cheng-Yuan Peng)、(Tsung-Hui Hu)、(Gin-Ho Lo)、(Horng-Yuan Wang)、(Jyh-Jou Chen)、(Jenny C. Yang)、(Steven J. Knox)、(Lingling Han)、(Hongmei Mo)、(Anita Mathias)、(Diana M. Brainard)、(I-Shyan Sheen)、(Yu-Chun Hsu)、(Chi-Jen Chu)、(Wan-Long Chuang)*,A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection,LIVER INTERNATIONAL,2016 Aug,36(8):
SCI論文 (Wan-Long Chuang)、(Rong-Nan Chien)、彭成元(Cheng-Yuan Peng)、(Ting-Tsung Chang)、(Gin-Ho Lo)、(I-Shyan Sheen)、(Horng-Yuan Wang)、(Jyh-Jou Chen)、(Jenny C. Yang)、(Steven J. Knox)、(Bing Gao)、(Kimberly L. Garrison)、(Hongmei Mo)、(Phillip S. Pang)、(Yu-Chun Hsu)、(Tsung-Hui Hu)、(Chi-Jen Chu)、(Jia-Horng Kao)*,Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus,JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY,2016 Jul,31(7):1323-1329
SCI論文 (Jia-Horng Kao)*、(Donald M. Jensen)、(Michael P. Manns)、(Ira Jacobson)、(Hiromitsu Kumada)、(Joji Toyot)、(Jeong Heo)、(Boris Yoffe)、(William Sievert)、(Fernando Bessone)、彭成元(Cheng-Yuan Peng)、(Stuart K. Roberts)、(Youn-Jae Lee)、(Ra?a Bhore)、(Patricia Mendez)、(Eric Hughes)、(Stephanie Noviello),Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis,LIVER INTERNATIONAL,2016 Jul,36(7):954-62
SCI論文 (Kuo-Chih Tseng)、(Chih-Wei Tseng)、(Tsai-Yuan Hsieh)、彭成元(Cheng-Yuan Peng)、(Chih-Lin Lin)、(Tung-HungSu)、(Tai-Chung Tseng)、(Hans Hsienhong Lin)、(Chia-Chi Wang)、(Jia-Horng Kao)*,Efficacy of entecavir therapy for HBeAg-positive chronic hepatitis B patients with prior exposure to interferon or nucleos(t)ide analogues,HEPATOLOGY RESEARCH,2016 Jun,46(7):642-649
SCI論文 蕭望德(Won-Der Shau)、彭成元(Cheng-Yuan Peng)、莊伯恒(Po-Heng Chuang)、賴學洲(Hsueh-Chou Lai)、鄭庚申(Ken-Sheng Cheng)、周仁偉(Jen-Wei Chou)、陳洋源(Yang-Yuan Chen)、余承儒(Cheng-Ju Yu)、馮俊龍(Chun-Lung Feng)、蘇文邦(Wen-Pang Su)、陳昇弘(Sheng-Hung Chen)、高榮達(Jung-Ta Kao)*,Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study,BMC GASTROENTEROLOGY,2016 Apr,.(.):
Other論文 丁俊夫(Chun-Fu Ting)、高榮達(Jung-Ta Kao)*、黃文信(Wen-Hsin Huang)、馮俊龍(Chun-Lung Feng)、余承儒(Cheng-Ju Yu)、彭成元(Cheng-Yuan Peng)、蘇文邦(Wen-Pang Su)、賴學洲(Hsueh-Chou Lai)、鄭庚申(Ken-Sheng Cheng)、莊伯恒(Po-Heng Chuang),Clinical factors associated with the survival of patients with intrahepatic cholangiocarcinoma,Advances in Digestive Medicine,2016 Mar,():
SCI論文 (Henry L.Y. Chan)、(Sang Hoon Ahn)、(Ting-Tsung Chang)、彭成元(Cheng-Yuan Peng)、(David Wong)、(Carla S. Cof?n)、(Seng Gee Lim)、(Pei-Jer Chen)、(Harry L.A. Janssen)、(Patrick Marcellin)、(Lawrence Serfaty)、(Stefan Zeuzem)、(David Cohen)、(Linda Critelli)、(Dong Xu)、(Megan Wind-Rotolo)、(Elizabeth Cooney)*,Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B),JOURNAL OF HEPATOLOGY,2016 Mar,64(5):1011-1019
SCI論文 (Chia-Chi Wang)、(Chih-Lin Lin)、(Tsai-Yuan Hsieh)、(Kuo-Chih Tseng)、彭成元(Cheng-Yuan Peng)、(Tung-Hung Su)、(Sheng-Shun Yang)、(Yu-Chun Hsu)、(Tsung-Ming Chen)、(Jia-Horng Kao)*,Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan,Hepatology International,2016 Mar,10(2):294-301
SCI論文 林文元(Wen-Yuan Lin)、彭成元(Cheng-Yuan Peng)、林正介(Cheng-Chieh Lin)、(Lance E. Davidson)、(F. Xavier Pi-Sunyer)、(Pei-Kun Sung)、(Kuo-Chin Huang)*,General and Abdominal Adiposity and Risk of Death in HBV versus non-HBV Carriers: A 10-Year Population-Based Cohort Study,MEDICINE,2016 Jan,95(2):e2162
SCI論文 蕭博任(Po-Jen Hsiao)、謝博帆(Po-Fan Hsieh)、鄒頡龍(Chieh-Lung Chou)*、賴學洲(Hsueh-Chou Lai)*、彭成元(Cheng-Yuan Peng)、蘇冠賓(Kuan-Pin Su),Anti-viral therapy and decreased sexual desire in patients with chronic hepatitis C,PLoS One,2016 ,():
SCI論文 陳益程(Yi-Cheng)、彭成元(Cheng-Yuan Peng)、鄭文睿(Wen-Juei Jeng)、簡榮南(Ron-Nan Chien)、廖運範(Yun-Fan Liaw)*,Clinical outcomes after interruption of entecavir therapy in HBeAg-negative chronic hepatitis B patients with compensated cirrhosis,ALIMENTARY PHARMACOLOGY & THERAPEUTICS,2015 Nov,42(10):1182-1191
SCI論文 陳昇弘(Sheng-Hung Chen)、彭成元(Cheng-Yuan Peng)*、賴學洲(Hsueh-Chou Lai)、江宜平(I-Ping Chiang)、李瓊如、蘇文邦(Wen-Pang Su)、林佳欣、高榮達(Jung-Ta Kao)、莊伯恒(Po-Heng Chuang),Head-to-Head Comparison between Collagen Proportionate Area and Acoustic Radiation Force Impulse Elastography in Liver Fibrosis Quantification in Chronic Hepatitis C,PLoS One,2015 Oct,10(10):e0140554-e0140554
SCI論文 (Jean-Michel Pawlotsky)*、(Robert Flisiak)、(Shiv K. Sarin)、(Jens Rasenack)、(Teerha Piratvisuth)、(Wan-LongChuang)、彭成元(Cheng-Yuan Peng)、(Graham R. Foster)、(Samir Shah)、(Heiner Wedemeyer)、(Christophe Hezode)、(Wei Zhang)、(Kelly A. Wong)、(Bin Li)、(Claudio Avila)、(Nikolai V. Naoumov),Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection,HEPATOLOGY,2015 Oct,62(4):1013-1023
SCI論文 (Chi-Chieh Yang)、(Wei-Lun Tsai)、(Wei-Wen Su)、(Chung-Feng Huang)、(Pin-Nan Cheng)、(Ching-Chu Lo)、(Kuo-Chih Tseng)、(Lein-Ray Mo)、(Chun-Hsiang Wang)、(Shi-hJer Hsu)、賴學洲(Hsueh-Chou Lai)、(Chien-Wei Su)、(Chun-Jen Liu)、彭成元(Cheng-Yuan Peng)、(Ming-Lung Yu)*,Rapid prediction of treatment futility of boceprevir with peginterferon-ribavirin for Taiwanese treatment experienced hepatitis C virus genotype 1-infected patients,PLoS One,2015 Sep,10(9):e0137852
SCI論文 彭成元(Cheng-Yuan Peng)、謝宗成(Tsung-Cheng Hsieh)、謝財源(Tsai-Yuan Hsieh)、曾國枝(Kuo-Chih Tseng)、林志陵(Chih-Lin Lin)、蘇東弘(Tung-Hung Su)、曾岱宗(Tai-Chung Tseng)、林憲宏(Hans Hsienhong Lin)、王嘉齊(Chia-Chi Wang)*、高嘉宏(Jia-Horng Kao)*,HBV-DNA Level at 6 Months of Entecavir Treatment Predicts HBeAg Loss in HBeAg-Positive Chronic Hepatitis B Patients,JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION,2015 Apr,114(4):308-313
SCI論文 葉明倫(Ming-Lun Yeh)、彭成元(Cheng-Yuan Peng)、戴嘉言(Chia-Yen Dai)、賴學洲(Hsueh-Chou Lai)、黃釧峰(Chung-Feng Huang)、謝明彥(Ming-Yen Hsieh)、黃志富(Jee-Fu Huang)、陳信成(Shinn-Cherng Chen)、林子堯(Zu-Yau Lin)、余明隆(Ming-Lung Yu)*、莊萬龍(Wan-Long Chuang)*,Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients,PLoS One,2015 Apr,10(4):e0122259
SCI論文 陳昇弘(Sheng-Hung Chen)、彭成元(Cheng-Yuan Peng)*、賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、林佳欣、李郁芬(Yu-Fen Li)、莊伯恒(Po-Heng Chuang)、陳景祥(Ching-Hsiang Chen),An Index to Predict Ribavirin-induced Anemia in Asian Patients With Chronic Genotype 1 Hepatitis C,Hepatitis Monthly,2015 Mar,15(3):e27148-e27148
SCI論文 鄭隆賓(Long-Bin Jeng)*、THORAT ASHOK(THORAT ASHOK)*、楊宏仁(Horng-Ren Yang)、葉俊杰(Chun-Chieh Yeh)、陳德鴻(Te-Hong Chen)、許家豪(Chia-Hao Hsu)、許士超(Shih-Chao Hsu)、潘健成(Kin-Shing Poon)、李秉純(Ping-Chun Li)、賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、彭成元(Cheng-Yuan Peng),Successful use of hepatitis B surface antigen-positive liver grafts - an effective source for donor organs in endemic areas: a single-center experience,Annals of Transplantation,2015 Feb,20():103-111
SCI論文 (Marcellin P)*、(Wursthorn K)、(Wedemeyer H)、(Chuang WL)、(Lau G)、(Avila C)、彭成元(Cheng-Yuan Peng)、(Gane E)、(Lim SG)、(Fainboim H)、(Foster GR)、(Safadi R)、(Rizzetto M)、(Manns M)、(Bao W)、(Naoumov N),Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B was associated with unexpected high rate of peripheral neuropathy,JOURNAL OF HEPATOLOGY,2015 Jan,62(1):41-47
SCI論文 (Manns M)*、(Pol S)、(Jacobson IM)、(Marcellin P)、(Gordon SC)、彭成元(Cheng-Yuan Peng)、(Chang TT)、(Everson GT)、(Heo J)、(Gerken G)、(Yoffe B)、(Towner WJ)、(Bourliere M)、(Metivier S)、(Chu CJ)、(Sievert W)、(Bronowicki JP)、(Thabut D)、(Lee YJ)、(Kao JH)、(McPhee F)、(Kopit J)、(Mendez P)、(Linaberry M)、(Hughes E)、(Noviello S),All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study,LANCET,2014 Nov,384(9954):1597-1605
SCI論文 (Chun-Jen Liu)、(Juliana Chang)、(Po-Huang Lee)、(Deng-Yn Lin)、(Cheng-Chung Wu)、鄭隆賓(Long-Bin Jeng)、(Yih-Jyh Lin)、(King-Tong Mok)、(Wei-Chen Lee)、(Hong-Zen Yeh)、(Ming-Chih Ho)、(Sheng-Shun Yang)、楊美都(Mei-Due Yang)、(Ming-Chin Yu)、(Rey-Heng Hu)、彭成元(Cheng-Yuan Peng)、(Kuan-Lang Lai)、(Stanley Shi-Chung Chang)、(Pei-Jer Chen)*,Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence,WORLD JOURNAL OF GASTROENTEROLOGY,2014 Aug,28(32):11384-11393
SCI論文 (Lee CM)、(Chen CY)、(Chien RN)、(Tseng KC)、彭成元(Cheng-Yuan Peng)、(Tung SY)、(Fang YJ)、(Huang YH)、(Lu SN)、(Hung CH)、(Tsai TJ)、(Fang CC)、(Hsu CW)、(Yeh CT)*,A double-blind randomized controlled study to evaluate the efficacy of low-dose oral interferon-alpha in preventing hepatitis C relapse,JOURNAL OF INTERFERON AND CYTOKINE RESEARCH,2014 Mar,34(3):187-194
SCI論文 賴學洲(Hsueh-Chou Lai)、林則成(Che-Chen Lin,)、鄭庚申(Ken-Sheng Cheng)、高榮達(Jung-Ta Kao)、周仁偉(Jen-Wei Chou)、彭成元(Cheng-Yuan Peng)、賴世偉(Shih-Wei Lai)、陳培君(Pei-Chun Chen)*、宋鴻樟(Fung-Chang Sung)*,Increased Incidence of Gastrointestinal Cancers Among Patients With Pyogenic Liver Abscess: A Population-Based Cohort Study,GASTROENTEROLOGY,2014 Jan,146(1):129-137
SCI論文 蘇冠賓(Kuan-Pin Su)、賴學洲(Hsueh-Chou Lai)、楊惠婷(Hui-Ting Yang)、蘇文邦(Wen-Pang Su)、彭成元(Cheng-Yuan Peng)、張倍禎(Jane Pei-Chen Chang)、(Chang HC)、(Pariante CM)*,Omega-3 fatty acids in the prevention of interferon-alpha-induced depression Results from a randomized, controlled trial,BIOLOGICAL PSYCHIATRY,2014 Jan,76(7):559-566
SCI論文 (Chien RN)、彭成元(Cheng-Yuan Peng)、(Kao JH)、(Hu TH)、(Lin CC)、(Hu CT)、(Chen CY)、(Hsieh TY)、(Lin HC)、(Chuang WL)*,Higher adherence with 3-year entecavir treatment than lamivudine or telbivudine in treatment-naïve Taiwanese patients with chronic hepatitis B,JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY,2014 Jan,29(1):185-192
SCI論文 彭成元(Cheng-Yuan Peng)、(Ter-Hsin Chen)、林雲冰(Yun-Ping Lim)、蔡輔仁(Fuu-Jen Tsai)*、林維勇(Wei-Yong Lin)、廖文伶(WEN-LING LIAO)、萬磊(Lei Wan)*,Association of MRC-1 and IL-28B with the treatment outcome of hepatitis C: a case control study,BMC GASTROENTEROLOGY,2014 ,14():113
Other論文 (Pei-Yuan Su)、劉士任(Shih-Jen Liu)、(Yi-Hua Chen)、(Shun-Sheng Wu)、(Yao-Li Chen)、(Jhin-Ran Ke)、彭成元(Cheng-Yuan Peng)、佘玉萍(Yuh-Pyng Sher)*,Increased IL-8 and IL-1b in the bile of acute,BioMedicine,2013 Dec,3(4):181-185
SCI論文 (Lin T)、(Ibrahim W)、彭成元(Cheng-Yuan Peng)、(Finegold MJ)、(Tsai RY)*,A novel role of nucleostemin in maintaining the genome integrity of dividing hepatocytes during mouse liver development and regeneration,HEPATOLOGY,2013 Dec,58(6):2176-2187
Other論文 陳昇弘(Sheng-Hung Chen)、彭成元(Cheng-Yuan Peng)*、賴學洲(Hsueh-Chou Lai)、林佳欣(Chia-Hsin Lin)、高榮達(Jung-Ta Kao)、莊伯恒(Po-Heng Chuang)、蘇文邦(Wen-Pang Su)、林志明(Chih-Ming Lin)、陳景祥(Ching-Hsiang Chen),THE ASSOCIATION BETWEEN SINGLE-NUCLEOTIDE POLYMORPHISMS IN THE INOSINE TRIPHOSPHATE PYROPHOSPHATASE GENE AND RIBAVIRIN (RBV)-INDUCED HEMOLYTIC ANEMIA IN GENOTYPE 2 HEPATITIS C VIRUS-INFECTED TAIWANESE PATIENTS RECEIVING PEGYLATED INTERFERON AND RBV COMBIN,臺灣消化醫學雜誌,2013 Sep,30(3):256-266
SCI論文 賴學洲(Hsueh-Chou Lai)、張仕妮(Shih-Ni Chang)、林則成(Che-Chen Lin)、陳清助(Ching-Chu Chen)、周仁偉(Jen-Wei Chou)、彭成元(Cheng-Yuan Peng)、賴世偉(Shih-Wei Lai)、宋鴻樟(Fung-Chang Sung)、李郁芬(Yu-Fen Li)*,Does diabetes mellitus with or without gallstones increase the risk of gallbladder cancer? Results from a population-based cohort study,JOURNAL OF GASTROENTEROLOGY,2013 Jul,48(7):856-865
SCI論文 林雲冰(Yun-Ping Lim)、(Yu-An Hsu)、(Kun-Hsi Tsai)、蔡輔仁(Fuu-Jen Tsai)*、彭成元(Cheng-Yuan Peng)、廖文伶(WEN-LING LIAO)、洪東榮(Hung, Dong-Zong)、田霓(Tien Ni)、(Chien-Yih Lin)*、萬磊(Lei Wan)*,The impact of polymorphisms in STAT6 on treatment outcome in HCV infected Taiwanese Chinese.,BMC IMMUNOLOGY,2013 May,14(21):1-9
SCI論文 (Yang HC)、(Chen CL)、(Shen YC)、彭成元(Cheng-Yuan Peng)、(Liu CJ)、(Tseng TC)、(Su TH)、(Chuang WL)、(Yu ML)、(Dai CY)、(Liu CH)、(Chen PJ)、(Chen DS)、(Kao JH)*,Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced HBeAg seroconversion,HEPATOLOGY,2013 Mar,57(3):934-943
SCI論文 (Wang CC)、(Tseng KC)、彭成元(Cheng-Yuan Peng)、(Hsieh TY)、(Lin CL)、(Su TH)、(Tseng TC)、(Hsu CS)、(Lin HH)、(Kao JH)*,Viral load and ALT correlate with serologic response in chronic hepatitis B patients treated with entecavir,JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY,2013 Jan,28(1):46-50
SCI論文 (Quan Yuan)、(Liu-Wei Song)、(Chun-Jen Liu)、(ZhuoLi)、(Ping-Guo Liu,)、(Cheng-Hao Huang)、(YanYan)、(Sheng-Xiang Ge)、(Ying-Bin Wang)、彭成元(Cheng-Yuan Peng)、(Jun Zhang)*、(Jia-Horng Kao)、(Ding-ShinnChen)、(Pei-Jer Chen)、(Ning-Shao Xia),Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients,GUT,2013 Jan,62(1):182-184
SCI論文 林雲冰(Yun-Ping Lim)、彭成元(Cheng-Yuan Peng)、廖文伶(WEN-LING LIAO)、洪東榮(Hung, Dong-Zong)、田霓(Tien Ni)、陳清玉(Cing-Yu Chen)、(Chang SY)、(Chang CY)、蔡輔仁(Fuu-Jen Tsai)*、萬磊(Lei Wan)*,Genetic variation in NOS2A is associated with a sustained virological response to peginterferon plus ribavirin therapy for chronic hepatitis C in Taiwanese Chinese.,JOURNAL OF MEDICAL VIROLOGY,2013 ,Epub(Epub):1-9
SCI論文 林雲冰(Yun-Ping Lim)、蔡輔仁(Fuu-Jen Tsai)、廖文伶(WEN-LING LIAO)、田霓(Tien Ni)、洪東榮(Hung, Dong-Zong)、彭成元(Cheng-Yuan Peng)*、萬磊(Lei Wan)*,Association of genetic variations in GNB1 with response to peginterferon plus ribavirin therapy for chronic hepatitis C in a Chinese population in Taiwan.,BMC GASTROENTEROLOGY,2012 Dec,12(167):1-11
Other論文 陳洋源(Yang-Yuan Chen)*、陳政國(Cheng-Kuo Chen)、彭成元(Cheng-Yuan Peng)、陳自諒(William Tzu-Liang Chen)、(Pei-Yi Chu),Unusual rectal submucosal tumor in melanosis coli,BioMedicine,2012 Dec,2(4):174-176
SCI論文 陳昇弘(Sheng-Hung Chen)、李郁芬(Yu-Fen Li)、賴學洲(Hsueh-Chou Lai)、高榮達(Jung-Ta Kao)、彭成元(Cheng-Yuan Peng)*、莊伯恒(Po-Heng Chuang)、蘇文邦(Wen-Pang Su)、江宜平(I-Ping Chiang),Noninvasive Assessment of Liver Fibrosis via Spleen Stiffness Measurement using Acoustic Radiation Force Impulse Sonoelastography in Patients with Chronic Hepatitis B or C,JOURNAL OF VIRAL HEPATITIS,2012 Sep,19(9):654-663
SCI論文 陳昇弘(Sheng-Hung Chen)、李郁芬(Yu-Fen Li)、賴學洲(Hsueh-Chou Lai)、高榮達(Jung-Ta Kao)、彭成元(Cheng-Yuan Peng)*、莊伯恒(Po-Heng Chuang)、蘇文邦(Wen-Pang Su)、江宜平(I-Ping Chiang),Effects of patient factors on noninvasive liver stiffness measurement using acoustic radiation force impulse elastography in patients with chronic hepatitis C,BMC GASTROENTEROLOGY,2012 Aug,12(1):105-105
SCI論文 彭成元(Cheng-Yuan Peng)、簡榮南(Rong-Nan Chien)、廖運範(Yun-Fan Liaw)*,Hepatitis B virus-related decompensated liver disease: Benefits of antiviral therapy,JOURNAL OF HEPATOLOGY,2012 Aug,57(2):442-450
SCI論文 賴學洲(Hsueh-Chou Lai)、I-Ju Tsai(蔡怡儒)、陳培君(Pei-Chun Chen)、莫之欣、周仁偉(Jen-Wei Chou)、彭成元(Cheng-Yuan Peng)、賴世偉(Shih-Wei Lai)、宋鴻樟(Fung-Chang Sung)、呂淑妤(Shu-Yu Lyu)*、(Donald E. Morisky),Gallstones, a cholecystectomy, chronic pancreatitis, and the risk of subsequent pancreatic cancer in diabetic patients: a population-based cohort study,JOURNAL OF GASTROENTEROLOGY,2012 Aug,():
SCI論文 高榮達(Jung-Ta Kao)、賴學洲(Hsueh-Chou Lai)、蔡淑美(Shu-Mei Tsai)、林佩昭(Pei-Chao Lin)、莊伯恒(Po-Heng Chuang)、余承儒(Cheng-Ju Yu)、鄭庚申(Ken-Sheng Cheng)、蘇文邦(Wen-Pang Su)、許秉寧(Ping-Ning Hsu)、彭成元(Cheng-Yuan Peng)、吳怡瑩(WU YI-YING)*,Rather than interleukin-27, interleukin-6 expresses positive correlation with liver severity in naı¨ve hepatitis B infection patients,LIVER INTERNATIONAL,2012 Jul,32(6):928-936
SCI論文 彭成元(Cheng-Yuan Peng)*,Commentary: HBsAg levels as predictor of sustained response to peginterferon in HBeAg-negative chronic hepatitis B - author's reply,ALIMENTARY PHARMACOLOGY & THERAPEUTICS,2012 Apr,35():839-851
SCI論文 潘健成(Kin-Shing Poon)、鄭隆賓(Long-Bin Jeng)*、陳德鴻(Te-Hong Chen)、楊宏仁(Horng-Ren Yang)、李秉純(Ping-Chun Li)、李靜枝、葉俊杰(Chun-Chieh Yeh)、賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、彭成元(Cheng-Yuan Peng)、陳永芳(Yung-Fang Chen)、何永仁(Yung-Jen Ho)、蔡伯邦(Po-Pang Tsai),A High Model for End-stage Liver Disease Score Should Not Be Considered a Contraindication to Living Donor Liver Transplantation,TRANSPLANTATION PROCEEDINGS,2012 Mar,44(1):316-319
SCI論文 李秉純(Ping-Chun Li)、鄭隆賓(Long-Bin Jeng)*、楊宏仁(Horng-Ren Yang)、李靜枝(Ching-Chih Lee)、潘健成(Kin-Shing Poon)、陳德鴻(Te-Hong Chen)、葉俊杰(Chun-Chieh Yeh)、賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、彭成元(Cheng-Yuan Peng)、陳永芳(Yung-Fang Chen)、何永仁(Yung-Jen Ho),Hepatic artery reconstruction in living donor liver transplantation: running suture under surgical loupes by cardiovascular surgeons in 180 recipients,TRANSPLANTATION PROCEEDINGS,2012 Mar,44(2):448-450
SCI論文 楊宏仁(Horng-Ren Yang)、鄭隆賓(Long-Bin Jeng)*、李秉純(Ping-Chun Li)、李靜枝(Ching-Chih Lee)、潘健成(Kin-Shing Poon)、陳德鴻(Te-Hong Chen)、葉俊杰(Chun-Chieh Yeh)、賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、彭成元(Cheng-Yuan Peng)、陳永芳(Yung-Fang Chen)、何永仁(Yung-Jen Ho),Living Donor Right Hepatectomy With Inclusion of the Middle Hepatic Vein: Outcome in 200 Donors,TRANSPLANTATION PROCEEDINGS,2012 Mar,44(2):460-462
SCI論文 彭成元(Cheng-Yuan Peng)*、賴學洲(Hsueh-Chou Lai)、李郁芬(Yu-Fen Li)、蘇文邦(Wen-Pang Su)、莊伯恒(Po-Heng Chuang)、高榮達(Jung-Ta Kao),Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B,ALIMENTARY PHARMACOLOGY & THERAPEUTICS,2012 Feb,35(4):458-468
SCI論文 蘇啟成(Khay-Seng Soh)、鄭隆賓(Long-Bin Jeng)*、楊宏仁(Horng-Ren Yang)、李秉純(Ping-Chun Li)、李靜枝(Lee Ching Chih)、潘健成(Kin-Shing Poon)、陳德鴻(Te-Hong Chen)、葉俊杰(Chun-Chieh Yeh)、賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、彭成元(Cheng-Yuan Peng)、陳永芳(Yung-Fang Chen)、何永仁(Yung-Jen Ho),Simultaneous Liver and Kidney Transplantation From Different Living Donors,TRANSPLANTATION PROCEEDINGS,2012 ,44(2):509-511
Other論文 林晏年(Yen-Nien Lin)、周仁偉(Jen-Wei Chou)*、鄭庚申(Ken-Sheng Cheng)*、彭成元(Cheng-Yuan Peng)、鄭隆賓(Long-Bin Jeng)、江宜平(I-Ping Chiang),Treatment of Fulminant Autoimmune Hepatitis: Corticosteroid Therapy or Liver Transplantation? A Case Report andLiterature Review,Gastroenterology Research,2011 Oct,4(5):231-235
SCI論文 黃文信(Wen-Hsin Huang)*、林智一(Tze-Yi Lin)、彭成元(Cheng-Yuan Peng),Chronic skin ulcer revealing metastasis from gastric cancer,Clinical Gastroenterology and Hepatology,2011 Sep,9(9):e86-e87
SCI論文 韓至強(Eric C. Han)、李英雄(Ying-shiung Lee)、劉玉晴(Yu-Ching Liu)、廖欣儀(Hsin-Yi Liao)、廖彣欣(Wen-Sin Liao)、賴學洲(Hsueh-Chou Lai)、彭成元(Cheng-Yuan Peng)*、鄭隆賓(Long-Bin Jeng),Mass spectrometry-based plasma peptide profiling of acute exacerbation in HBeAg-positive chronic hepatitis B,CLINICA CHIMICA ACTA,2011 Aug,412(23-24):2174-2182
SCI論文 廖運範(Yun-Fan Liaw)*、(Maria Raptopoulou-Gigi)、(Hugo Cheinquer)、(Shiv Kumar Sarin)、(Tawesak Tanwandee)、(Nancy Leung)、彭成元(Cheng-Yuan Peng)、(Robert P. Myers)、(Robert S. Brown Jr)、(Lennox Jeffers)、(Naoky Tsai)、(Jolanta Bialkowska)、(Shijie Tang)、(Suzanne Beebe)、(Elizabeth Cooney),Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open-label study,HEPATOLOGY,2011 Jul,54(1):91-100
SCI論文 (Keyur Patel)*、(Alexander J Thompson)、(Wan-Long Chuang)、(Chuan-Mo Lee)、彭成元(Cheng-Yuan Peng)、(Ganesananthan Shanmuganathan)、(Satawat Thongsawat)、(Tawesak Tanwandee)、(Varocha Mahachai)、(Chutima Pramoolsinsap)、(Mong Cho)、(Kwang Hyup Han)、(Samir R Shah)、(Graham R Foster)、(Paul J Clark)、(Erik Pulkstenis)、(G. Mani Subramanian)、(John G McHutchison),Insulin resistance is independently associated with significant hepatic fibrosis in Asian chronic hepatitis C genotype 2 or 3 patients,JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY,2011 Jul,26(7):1182-1188
SCI論文 林晏年(Yen-Nien Lin)、周仁偉(Jen-Wei Chou)*、莊伯恒(Po-Heng Chuang)、鄭庚申(Ken-Sheng Cheng)、彭成元(Cheng-Yuan Peng)、江宜平(I-Ping Chiang),Primary small intestinal natural killer/t cell lymphoma mimicking tuberculous peritonitis: report of a case and review of the literature.,INTERNAL MEDICINE,2011 Mar,50(5):515-518
SCI論文 彭成元(Cheng-Yuan Peng)*、陳志濱(Chih-Bin Chen)、賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、莊伯恒(Po-Heng Chuang)、吳宏達(Hong-Dar Isaac Wu)、鄭隆賓(Long-Bin Jeng),Predictors for early HBeAg loss during lamivudine therapy in HBeAg-positive chronic hepatitis B patients with acute exacerbation.,Hepatology International,2011 Mar,5(1):586-596
Other論文 馮俊龍(Chun-Lung Feng)、黃文信(Wen-Hsin Huang)、周仁偉(Jen-Wei Chou)*、余承儒(Cheng-Ju Yu)、彭成元(Cheng-Yuan Peng)、陳永芳(Yung-Fang Chen),The prevalence of colonic diverticular disease in patients with bowel symptoms,臺灣消化醫學雜誌,2010 Sep,27(3):261-266
SCI論文 黃文信(Wen-Hsin Huang)*、馮俊龍(Chun-Lung Feng)、賴學洲(Hsueh-Chou Lai)、余承儒(Cheng-Ju Yu)、周仁偉(Jen-Wei Chou)、彭成元(Cheng-Yuan Peng)、楊美都(Mei-Due Yang)、江宜平(I-Ping Chiang),Endoscopic ligation and resection for the treatment of small EUS-suspected gastric GI stromal tumors,GASTROINTESTINAL ENDOSCOPY,2010 May,71(6):1076-1081
SCI論文 蘇冠賓(Kuan-Pin Su)*、黃士懿(Shih-Yi Huang)、彭成元(Cheng-Yuan Peng)、賴學洲(Hsueh-Chou Lai)、黃介良(Chieh-Liang Huang)、陳枻志(Yi-Chih Chen)、(Katherine J. Aitchison)、(Carmine M. Pariante),Phospholipase A2 and cyclo-oxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels,BIOLOGICAL PSYCHIATRY,2010 Mar,67(6):550-557
SCI論文 余承儒(Cheng-Ju Yu)、王煌輝、周仁偉(Jen-Wei Chou)*、賴學洲(Hsueh-Chou Lai)、黃文信(Wen-Hsin Huang)、彭成元(Cheng-Yuan Peng)、鄭庚申(Ken-Sheng Cheng)、陳永芳(Yung-Fang Chen),Phlebosclerotic colitis with nonsurgical treatment,INTERNATIONAL JOURNAL OF COLORECTAL DISEASE,2009 Oct,24(10):1241-1242
SCI論文 賴學洲(Hsueh-Chou Lai)、蔡金記(Chin-Chi Tsai)、馮俊龍(Chun-Lung Feng)、余承儒(Cheng-Ju Yu)、周仁偉(Jen-Wei Chou)*、黃文信(Wen-Hsin Huang)、徐章虎(Chang-Hu Hsu)、鄭庚申(Ken-Sheng Cheng)、彭成元(Cheng-Yuan Peng),Epigastric pain in a man with previous subtotal gastrectomy,GUT,2009 Oct,58(10):1332-1436
SCI論文 (Siwaporn Chainuvati)、(Jun Cheng)、(Jin Lin Hou)、(Chao-Wei Hsu)、(Ji Dong Jia)、(Piyawat Komolmit)、(So Young Kwon)、(Chang Hong Lee)、(Hong Li)*、(Ying Li)、(Chun-Jen Liu)、(Boon Leong Neo)、彭成元(Cheng-Yuan Peng)、(Tawesak Tanwandee)、(Suchat Wongcharatrawee)、(Jaw-Ching Wu)、(Ming-Lung Yu)、(Xin Xin Zhang),Patterns of managing chronic hepatitis B treatment-related drug resistance: a survey of physicians in Mainland China, South Korea, Taiwan, and Thailand,Hepatology International,2009 Sep,3(3):453-460
SCI論文 萬磊(Lei Wan)、(Yung-Jen Kung)、林應如(Ying-Ju Lin)、廖秋菊(Chiu-Chu Liao)、許晉銓(Jinn-Chyuan Sheu)、蔡育勳(Yuhsin Tsai)、賴學洲(Hsueh-Chou Lai)、彭成元(Cheng-Yuan Peng)*、蔡輔仁(Fuu-Jen Tsai)*,Th1 and Th2 cytokines are elevated in HCV-infected SVR(–) patients treated with interferon-alpha,BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS,2009 Feb,379(4):855-860
SCI論文 劉俊人(Chun-Jen Liu)、李伯皇(Po-Huang Lee)、林燈寅(Deng-Yn Lin)、吳誠中(Cheng-Chung Wu)、鄭隆賓(Long-Bin Jeng)、林炳文(Pin-Wen Lin)、莫景棠(King-Tong Mok)、李威震(Wei-Chen Lee)、葉宏仁(Hong-Zen Yeh)、何明志(Ming-Chih Ho)、(Sheng-Shun Yang)、李靜枝(Ching-Chih Lee)、游明晉(Ming-Chin Yu)、胡瑞恆(Rey-Heng Hu)、彭成元(Cheng-Yuan Peng)、(Kuan-Lang Lai)、(Stanley Shi-Chung Chang)、陳培哲(Pei-Jer Chen)*,Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage,JOURNAL OF HEPATOLOGY,2009 Feb,50(5):958-968
SCI論文 (Nancy Leung)*、彭成元(Cheng-Yuan Peng)、(Hie-Won Hann)、(Jose Sollano)、(Judy Lao-Tan)、(Chao-Wei Hsu)、(Laurentius Lesmana)、(Man-Fung Yuen)、(Lennox Jeffers)、(Albert Min)、(Kimberly Mencarini)、(Ulysses Diva)、(Anne Cross)、(Richard Wilber)、(Juan Lopez-Talavera),Early Hepatitis B Virus DNA Reduction in Hepatitis B e Antigen–Positive Patients with Chronic Hepatitis B: A Randomized International Study of Entecavir Versus Adefovir,HEPATOLOGY,2009 Jan,49(1):72-79
SCI論文 蘇文邦(Wen-Pang Su)、彭成元(Cheng-Yuan Peng)*、賴學洲(Hsueh-Chou Lai)、廖光福(Kuan-Fu Liao)、黃文信(Wen-Hsin Huang)、莊伯恒(Po-Heng Chuang)、陳志濱(Chih-Bin Chen)、鄭隆賓(Long-Bin Jeng),Persistent Transaminase Elevations in Chronic Hepatitis C Patients with Virological Response during Peginterferon and Ribavirin Therapy,HEPATO-GASTROENTEROLOGY,2009 ,(56):798-801
SCI論文 周仁偉(Jen-Wei Chou)、余承儒(Cheng-Ju Yu)、莊伯恒(Po-Heng Chuang)、賴學洲(Hsueh-Chou Lai)*、徐章虎(Chang-Hu Hsu)、鄭庚申(Ken-Sheng Cheng)、彭成元(Cheng-Yuan Peng),Successful treatment of fosinopril-induced severe cholestatic jaundice with plasma exchange,ANNALS OF PHARMACOTHERAPY,2008 Dec,42(12):1887-1892
SCI論文 黃文信(Wen-Hsin Huang)*、彭成元(Cheng-Yuan Peng)、余承儒(Cheng-Ju Yu)、周仁偉(Jen-Wei Chou)、馮俊龍(Chun-Lung Feng),Endoloop-assisted unroofing for the treatment of symptomatic duodenal lipomas,GASTROINTESTINAL ENDOSCOPY,2008 Dec,68(6):1234-1236
SCI論文 周仁偉(Jen-Wei Chou)、馮俊龍(Chun-Lung Feng)、賴學洲(Hsueh-Chou Lai)*、蔡金記(Chin-Chi Tsai)、陳昇弘(Sheng-Hung Chen)、徐章虎(Chang-Hu Hsu)、鄭庚申(Ken-Sheng Cheng)、彭成元(Cheng-Yuan Peng)、鍾斌魁(Ping-Kuei Chung),Obscure Gastrointestinal Bleeding Caused by Small Bowel Lipoma,INTERNAL MEDICINE JOURNAL,2008 Sep,47(18):1601-1603
SCI論文 曾俊凱(Chun-Kai Tseng)、蘇文邦(Wen-Pang Su)、賴學洲(Hsueh-Chou Lai)、周仁偉(Jen-Wei Chou)*、馮俊龍(Chun-Lung Feng)、彭成元(Cheng-Yuan Peng)、陳永芳(Yung-Fang Chen),Superior Mesenteric Artery Syndrome Caused by Celiac Axis Compression Syndrome: A Case Report,EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY,2008 Jun,20(6):578-582
SCI論文 陳昇弘(Sheng-Hung Chen)、黃文信(Wen-Hsin Huang)*、馮俊龍(Chun-Lung Feng)、周仁偉(Jen-Wei Chou)、徐章虎(Chang-Hu Hsu)、彭成元(Cheng-Yuan Peng)、楊美都(Mei-Due Yang),Clinical Analysis of Ectopic Pancreas with Endoscopic Ultrasonography: An Experience in a Medical Center,JOURNAL OF GASTROINTESTINAL SURGERY,2008 May,12(5):877-881
SCI論文 蔡金記(Chin-Chi Tsai)、周仁偉(Jen-Wei Chou)*、江宜平(I-Ping Chiang)、賴學洲(Hsueh-Chou Lai)、彭成元(Cheng-Yuan Peng),Mesenteric phlebosclerosis,INTERNAL MEDICINE,2008 Feb,47(3):183-184
Other論文 黃文信(Wen-Hsin Huang)、彭成元(Cheng-Yuan Peng)*、廖光福(Kuan-Fu Liao)、郭麗芳(Lai-Fong Kok)、賴學洲(Hsueh-Chou Lai)、徐章虎(Chang-Hu Hsu),Endoloop-assisted removal of a large duodenal lipoma: Report of a case,臺灣消化醫學雜誌,2007 Dec,24(4):400-404
SCI論文 曾毓淇(Yu-Chi Tseng)、曾俊凱(Chun-Kai Tseng)、周仁偉(Jen-Wei Chou)*、賴學洲(Hsueh-Chou Lai)、徐章虎(Chang-Hu Hsu)、鄭庚申(Ken-Sheng Cheng)、彭成元(Cheng-Yuan Peng)、陳永芳(Yung-Fang Chen),A Rare Cause of Mesenteric Ischemia: Celiac Axis Compression Syndrome,INTERNAL MEDICINE,2007 Sep,15(46):1187-1190
SCI論文 賴世偉(Shih-Wei Lai)、張伍隆(Wu-Long Chang)、彭成元(Cheng-Yuan Peng)、廖光福(Kuan-Fu Liao)*,Viral hepatitis among male amphetamine-inhaling abusers,INTERNAL MEDICINE JOURNAL,2007 Jul,37(7):472-477
SSCI論文 吳博倫(Po-Lun Wu)、廖光福(Kuan-Fu Liao)、彭成元(Cheng-Yuan Peng)、(Pariante CM)、蘇冠賓(Kuan-Pin Su)*,Manic episode associated with citalopram therapy for interferon-induced depression in a patient with chronic hepatitis C infection.,GENERAL HOSPITAL PSYCHIATRY,2007 Jul,29(4):374-376
Other論文 周仁偉(Jen-Wei Chou)、徐章虎(Chang-Hu Hsu)、廖光福(Kuan-Fu Liao)、賴學洲(Hsueh-Chou Lai)*、鄭庚申(Ken-Sheng Cheng)、彭成元(Cheng-Yuan Peng)、楊美都(Mei-Due Yang)、陳永芳(Yung-Fang Chen),Gallstone ileus: report of two cases and review of the literature,World journal of gastroenterology : WJG,2007 Feb,13(8):1295-1298
MT論文 黃文信(Wen-Hsin Huang)、彭成元(Cheng-Yuan Peng)、廖光福(Kuan-Fu Liao)、賴學洲(Hsueh-Chou Lai),Endoloop-Assisted Removal of A Large Duodenal Lipoma : Report of A Case,Mid-Taiwan Journal of Medicine,2007 ,24(0):400-404
Other論文 賴學洲(Hsueh-Chou Lai)、陳祖裕*、彭成元(Peng,Cheng-Yuan)、廖光福(Liao,Kuan-Fu)、林忠義(Lin,Chung-Yi)、黃文信(Wen-Hsin Huang)、周仁偉(Jen-Wei Chou)、余承儒(Cheng-Ju Yu),The characteristics of medium to large hypovascular hepatocellular carcinoma,臺灣消化醫學雜誌,2006 Sep,23(3):184-192
SCI論文 廖光福(Liao,Kuan-Fu)、彭成元(Peng,Cheng-Yuan)、賴世偉(Shih-Wei Lai)*、張伍隆、許南榮(Hsu,Nan-Yung),Descriptive epidemiology of Hepatitis C Virus among male heroin abusers in Taiwan,SOUTHERN MEDICAL JOURNAL,2006 Apr,4(99):348-351
SCI論文 廖光福(Kuan-Fu Liao)*、彭成元(Cheng-Yuan Peng)、賴世偉(Lai-Hih Wei)、莊伯恒(Po-Heng Chuang)、賴學洲(Hsueh-chou Lai)、周仁偉(Heb-Wei Chou)、陳志濱(Chih-Pin Chen)、蘇文邦(Wen-Pang Su),The prevalence of Genotype of hepatitis C virus between IVDU and non-IVDU,JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY,2006 Mar,21(2):A122-A122
SCI論文 (CHII-SHYAN LAY)、(YANG-TE TSAI)、(FA-YAUH LEE)、(YI-LIANG LAI)、余承儒(Cheng-Ju Yu)、(CHIH-BIN CHEN)、彭成元(Cheng-Yuan Peng),Endoscopic variceal ligation versus propranolol in prophylaxis of first variceal bleeding in patients with cirrhosis,JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY,2006 Feb,21(2):413-419
Other論文 賴學洲(Hsueh-Chou Lai)、陳祖裕(Chan CY)*、彭成元(Cheng-Yuan Peng)、陳志濱(Chih-Bin Chen)、黃文信(Huang Wen-Hsin),Pyogenic liver abscess associated with large colonic tubulovillous adenoma,World journal of gastroenterology : WJG,2006 Jan,12(6):990-992
SCI論文 (Lee TH)、(Tai DI)、(Cheng CJ)、(Sun CS)、(Lin CY)、(Sheu MJ)、(Lee WP)、彭成元(Cheng-Yuan Peng)、(Wang AH)、(Tsai SL),Enhanced nuclear factor-kappa B-associated Wnt-1 expression in hepatitis B- and C-related hepatocarcinogenesis: identification by functional proteomics.,BRITISH JOURNAL OF BIOMEDICAL SCIENCE,2006 Jan,13(1):27-39
Other論文 陳偉德(Chen,Walter)、沈戊忠(Shen,Wu-Chung)、洪瑞松(Hung,Jui-Sung)、楊美都、陳安琪、彭成元(Peng,Cheng-Yuan)、林國瑞(Lin,Kuo-Juei)、林綽娟(Lin,Chouh-Jiuan)、蘇百弘、吳錫金(Wu,His-Chin)、許朝添(Chao-Tien Hsu)、黃水坤、林正介(Cheng-Chieh Lin)、蔡長海(Chang-Hai Tsai),新整合課程:分年、分段、分組教改之經驗及學生評論回饋分析,醫學教育,2005 Dec,9(4):320-332
Other論文 陳志濱(Chih-Bin Chen)、賴學洲(Hsueh-Chou Lai)*、彭成元(Cheng-Yuan Peng)、鄭隆賓(Long-Bin Jeng)、何永仁(Yung-Jen Ho)、江宜平(I-Ping Chiang),Primary hepatic carcinoid tumor: report of a case,臺灣消化醫學雜誌,2005 ,2(22):129-135
Other論文 黃文信、伍偉華、王煌輝(Hwang-Huei Wang)、江宜平、徐章虎、彭成元(Peng,Cheng-Yuan),Inflammatory fibroid polyp of the pylorus: report of a case,臺灣消化醫學雜誌,2004 Nov,21(4):255-262
Other論文 周仁偉(Jen-Wei Chou)、徐章虎(Chang-Hu Hsu)*、彭成元(Cheng-Yuan Peng)、楊美都(Mei-Due Yang)、何永仁(Yung-Jen Ho)、江宜平(I-Ping Chiang),Hemobilia caused by a ruptured pseudoaneurysm of hepatic artery: report of a case.,臺灣消化醫學雜誌,2004 Jun,21(2):147-154
SCI論文 (Shi-Ming Lin*)、(Chun-Jung Lin)、(Hock-Jean Chung)、(Chao-Wei Hsu)、彭成元(Cheng-Yuan Peng),Power rolloff during interactive radiofrequency ablation can enhance necrosis when treating hepatocellular carcinoma,AMERICAN JOURNAL OF ROENTGENOLOGY,2003 Jan,180(1):151-157
SCI論文 (Shi-Ming Lin*)、(Chien-Heng Shen)、(Deng-Yn Lin)、(Sow-Hsong Kuo)、(Chun-Jung Lin)、(Chao-Wei Hsu)、(Kock-Jean Chung)、彭成元(Cheng-Yuan Peng),Cytologic changes in small hepatocellular carcinomas after radiofrequency ablation,ACTA CYTOLOGICA,2002 May,46(3):490-494
SCI論文 彭成元(Cheng-Yuan Peng)、(Tse-Ching Chen)、(Shao-Pi Hung)、(Miin-Fu Chen)、(Chau-Ting Yeh)、(Sun-Lung Tsai)、(Chia-Ming Chu)、(Yun-Fan Liaw),Genetic alterations of INK4a/ARF locus and p53 in human hepatocellular carcinoma,ANTICANCER RESEARCH,2002 Mar,22(*):1265-1272
SCI論文 (Chau-Ting Yeh*)、(Su-Chuan Lu)、(Tse-Ching Chen)、彭成元(Cheng-Yuan Peng)、(Yun-Fan Liaw),Aberrant transcripts of the cyclin-dependent kinase-associated protein phosphatase in hepatocellular carcinoma,CANCER RESEARCH,2000 Sep,60(*):4697-4700
SCI論文 彭成元(Cheng-Yuan Peng)、(Sun-Lung Tsai)、(Chau-Ting Yeh)、(Shao-Pi Hung)、(Miin-Fu Chen)、(Tse-Ching Chen)、(Chia-Ming Chu)、(Yun-Fan Liaw*)*,Genetic alterations of p73 are infrequent but may occur in early stage hepatocellular carcinoma,ANTICANCER RESEARCH,2000 May,20(*):1487-1492
SCI論文 (Dar-In Tai)、(Sun-Lung Tsai*)、(Young-Mao Chen)、(Yen-Ling Chuang)、彭成元(Cheng-Yuan Peng)、(I-Shyan Sheen)、(Chau-Ting Yeh)、(Kenneth S S Chang)、(Shao-Nan Huang)、(George C Kuo),Activation of nuclear factor kB in hepatitis C virus infection: implications for pathogenesis and hepatocarcinogenesis,HEPATOLOGY,2000 Mar,31(31):656-664
SCI論文 (Chow PKH)*、(Gandhi M)、(Tan SB)、(Khin MW)、(Khasbazar A)、(Ong J)、(Choo SP)、(Cheow PC)、(Chotipanich C)、(Lim K)、(Lesmana LA)、(Manuaba TW)、(Yoong BK)、(Raj A)、(Law CS)、(Cua IHY)、(Lobo RR)、(Teh CSC)、(Kim YH)、(Jong YW)、(Han HS)、(Bae SH)、(Yoon HK)、(Lee RC)、(Hung CF)、彭成元(Peng, Cheng-Yuan)、(Liang PC)、(Bartlett A)、(Kok KYY)、(Thng CH)、(Low AS)、(Goh ASW)、(Tay KH)、(Lo RHG)、(Goh BKP)、(Ng DCE)、(Lekurwale G)、(Liew WM)、(Gebski V)、(Mak KSW)、(Soo KC),SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma,JOURNAL OF CLINICAL ONCOLOGY, ,():
 
研討會論文/Conference Papers
(發表主題或論文名稱,研討會名稱,演講地點,研討會期間,受邀演講題目)
1﹒ 以ARFI肝臟硬度測試接受治療慢性C型肝炎病患於治療中及治療後具有顯著肝臟硬度下降之現象,中華民國一○七年消化系聯合學術演講年會,台大醫院國際會議中心,2018.3.24 ~ 2018.3.25,
2﹒ Spleen stiffness and platelet count predict esophageal varices in patients with liver cirrhosis,中華民國一○七年消化系聯合學術演講年會,台大醫院國際會議中心,2018.3.24 ~ 2018.3.25,
3﹒ Efficacy and Safety of Direct-Acting Antivirals in Treatment-naïve and-experienced Patients with Chronic Hepatitis C: a real-world preliminary result,中華民國一O七年台灣消化系聯合學術演講年會,台大醫院國際會議中心,2018.3.24 ~ 2018.3.25,
4﹒ Modified Fibrosis-4 index stratifies the risk of hepatocellular carcinoma in Asian patients with chronic hepatitis B treated with entecavi,中華民國一O七年台灣消化系聯合學術演講年會,台大醫院國際會議中心,2018.3.24 ~ 2018.3.25,
5﹒ 非侵入性肝臟纖維化指標和聲幅射立脈波(ARFI)超音波在原發性膽汁性肝硬化患者之初步研究,中華民國一O七年台灣消化系聯合學術演講年會,台大醫院國際會議中心,2018.3.24 ~ 2018.3.25,
6﹒ ,The 16th World Federation for Ultrasound in Medicine and Biology Congress 2017,Taipei,2017.10.13 ~ 2017.10.17,
7﹒ Significant Annual Declines in Liver Stiffness on Acoustic Radiation Force-Impulse Elastography Over Five-year Surveillances in Patients Treated with Antiviral Nucleos(t)ide Analogs for Chronic Hepatitis B,2017 Taiwan Digestive Disease Week,NTUH International Convention Center, Taipei,2017.9.30 ~ 2017.10.1,Significant Annual Declines in Liver Stiffness on Acoustic Radiation Force-Impulse Elastography Over Five-year Surveillances in Patients Treated with Antiviral Nucleos(t)ide Analogs for Chronic Hepatitis B
8﹒ Long-term serum HBsAg kinetics in genotype B or C infected HBeAg-positive and –negative chronic hepatitis B patients following Pegasys therapy,2017台灣消化系醫學週,台大醫院國際會議中心,2017.9.30 ~ 2017.10.1,
9﹒ Treatment with direct-acting anti-viral agents is associated with increased platelet counts in chronic hepatitis C patients without cirrhosis,2017台灣消化系醫學週,台大醫院國際會議中心,2017.9.30 ~ 2017.10.1,
10﹒ COMPARISON OF THE INCIDENCES OF HBSAG LOSS AND HEPATOCELLAR CARCINOMA DEVELOPMENT BETWEEN HBEAG-NEGATIVE NON-CIRRHOTIC PATIENTS WHO DISCONTINUND OR CONTINUED ENTECVAIR THERAPY,2017 台灣消化醫學週,台大醫院國際會議中心,2017.9.29 ~ 2017.10.1,
11﹒ Changes of Renal Function During and After HCV Therapy with Peginterferon and Ribavirin and Its Influencing Factors,2017 台灣消化醫學週,台大醫院國際會議中心,2017.9.29 ~ 2017.10.1,
12﹒ The combination of noninvasive assessment for liver fibrosis in chronic viral hepatitis by using modified FIB-4 and acoustic radiation force impulse: a single-center experience,2017 台灣消化醫學週,台大醫院國際會議中心,2017.9.29 ~ 2017.10.1,
13﹒ TAIWANESE SUBGROUP ANALYSIS OF A PHASE 3 STUDY COMPARING TENOFOVIR ALAFENNAMIDE(TAF) TO TENOFOVIR DISOPROXIL FUMARIATE(TDF) IN PATIENTS WITH HBEAG-POSTIIVE, CHRONIC HEPATITIS B(CHB): EFFICACY AND SAFETY RESULTS AT WEEK 48,2017 台灣消化醫學週,台大醫院國際會議中心,2017.9.29 ~ 2017.10.1,
14﹒ ,5th ELITE WORKSHOP: Optimize HBV Management in Special Patient group,高雄市水晶棧國際酒店,2017.9.16 ~ 2017.9.17,
15﹒ ,2017 TASL Single Topic Conference,台大醫院國際會議中心,2017.6.17 ~ 2017.6.18,
16﹒ ,2017新知研討會Post EASL&APASL,台中林酒店6樓,2017.5.28 ~ 2017.5.28,
17﹒ ,106年台灣消化系聯合學術演講年會,台中榮民總醫院,2017.3.17 ~ 2017.3.19,ARFI肝臟硬度測試是否可做為預測以DAA等治療慢性C型肝炎之病毒學反應的顯著預測因子?Real-world Experiences
18﹒ PREDICTION OF CLINICAL OUTCOMES IN NUCLEOS(T)IDE ANALOGUE-NAÏ VE CHRONIC HEPATITIS PATIENTS WITH CIRRHOSIS TREATED WITH ENTECAVIR,中華民國一○六年消化系聯合學術演講年會,臺中榮民總醫院,2017.3.18 ~ 2017.3.19,
19﹒ Comparison of non-invasive indices for the prediction of liver fibrosis in chronic viral hepatitis,中華民國一○六年消化系聯合學術演講年會,臺中榮民總醫院,2017.3.18 ~ 2017.3.19,
20﹒ 使用貝樂克治療慢性B型肝炎之亞洲患者其肝細胞癌的風險預測模型,中華民國一○六年消化系聯合學術演講年會,臺中榮民總醫院,2017.3.18 ~ 2017.3.19,
21﹒ 人類C型凝集素CLEC18在慢性B型肝炎患者中肝臟及血將的表現,中華民國一○六年消化系聯合學術演講年會,臺中榮民總醫院,2017.3.18 ~ 2017.3.19,
22﹒ C型肝炎患者接受直接作用抗病毒藥物前後糖化血色素、血糖、胰島素阻抗、與血脂肪的變化,中華民國一○六年消化系聯合學術演講年會,臺中榮民總醫院,2017.3.18 ~ 2017.3.19,
23﹒ ,中華民國一○六年消化系聯合學術演講年會,臺中榮民總醫院,2017.3.18 ~ 2017.3.19,
24﹒ Glycohemoglobin, sugar, insulin resistance, and lipid profile in chronic hepatitis C patients treated with direct-acting antiviral agents,中華民國一○六年消化系聯合學術演講年會,台中榮民總醫院,2017.3.18 ~ 2017.3.19,
25﹒ ,Facing Hepatocellular Carcinoma: Challenges and Perspectives,台東馬偕紀念醫院,2016.12.17 ~ 2016.12.17,Secondary Prevention of HCC: HBV
26﹒ Evolution and Predictive Role of Basal Core Promoter and Precore Mutants in Genotype B or C Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients Undergoing Peginterferon Therapy,AASLD The LIVER MEETING 2016,BOSTON,2016.11.11 ~ 2016.11.15,
27﹒ ,Advance in Management of Chronic Hepatitis C and B in Taiwan,Taichung,2016.11.27 ~ 2016.11.27,
28﹒ Evolution and Predictive Role of Basal Core Promoter and Precore Mutants in Genotype B or C Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients Undergoing Peginterferon Therapy,2016 TDDW 台灣消化醫學週,台北,2016.10.1 ~ 2016.10.2,
29﹒ Group-based trajectory model to predict hepatitis B surface antigen loss during nucleos(t)ide analogue therapy in chronic hepatitis B patients,2016 TDDW 台灣消化醫學週,台北,2016.10.1 ~ 2016.10.2,
30﹒ Comparison of non-invasive indices for the prediction of liver cirrhosis in chronic viral hepatitis,2016 TDDW 台灣消化醫學週,台北,2016.10.1 ~ 2016.10.2,
31﹒ ,台灣消化醫學週,台北,2016.10.1 ~ 2016.10.1,The Role of Noninvasive Methods for the Evaluation of the Severity of Liver Disease in Treated and Untreated Patients
32﹒ ,TDDW 2016 台灣消化醫學週 (主持人),台北,2016.10.2 ~ 2016.10.2,The Journey to Optimize Hepatitis B Management
33﹒ Anti-viral therapy and decreased sexual desire in patients with chronic hepatitis C,2016 Taiwan Digestive Disease Week,台大醫學院國際會議中心,2016.9.30 ~ 2016.10.2,
34﹒ ,105年度第二場次肝臟暨消化道臨床與病理研討會,彰化(彰化秀傳醫院),2016.8.20 ~ 2016.8.20,
35﹒ ,4th ELITE workshop Optimize HBV Management in Special Patient Group,新竹(新竹喜來登),2016.8.20 ~ 2016.8.20,
36﹒ Long-term Serum HBsAg Kinetics in Chronic Hepatitis B Patients Who Achieve HBeAg Loss Following Pegasys Therapy,2016 APASL Single Topic Conference on Hepatitis C,Kaohsiung,2016.6.10 ~ 2016.6.10,
37﹒ ,2016 APASL Single Topic Conference on Hepatitis C (主持人),Kaohsiung,2016.6.10 ~ 2016.6.12,Before Cure(IV)- New Era of Treatment for CHC Patients in Special Population(主持人)
38﹒ 2016 Post EASL&APASL新知研討會(會議主持人),2016 Post EASL&APASL Meeting (教育演講)(會議主持人),Taichung,2016.5.15 ~ 2016.5.15,
39﹒ Recent Advance in ARFI-based Liver Fibrosis Quantification In Chronic Hepatitis B,TARFIT Workshop,台北榮民總醫院,2016.3.26 ~ 2016.3.26,Recent Advance in ARFI-based Liver Fibrosis Quantification In Chronic Hepatitis B
40﹒ 使用膠原蛋白面積比例定量肝臟纖維化: 慢性B型和C型肝炎之間的比較 Comparison of Collagen Proportionate Areas in Liver Fibrosis Quantification between Chronic Hepatitis B and C,中華民國一○五年消化系聯合學術演講年會,台北榮民總醫院,2016.3.27 ~ 2016.3.27,使用膠原蛋白面積比例定量肝臟纖維化: 慢性B型和C型肝炎之間的比較
41﹒ Long-term Serum HBsAg Kinetics in Chronic Hepatitis B Patients Who Achieve HBeAg Loss Following Pegasys Therapy,中華民國一○五年消化系聯合學術演講年會,台北(台北榮民總醫院),2016.3.26 ~ 2016.3.27,
42﹒ ,中華民國一○五年消化系聯合學術演講年會(主持人),台北(台北榮民總醫院),2016.3.26 ~ 2016.3.27,主題: B型肝炎(主持人)
43﹒ Sorafenib For Advanced Stage HCC : Real Life Practice Analysis in Single Medical Center ,中華民國一○五年消化系聯合學術演講年會,臺北榮民總醫院致德樓第三會議室,2016.3.26 ~ 2016.3.27,
44﹒ ,Advances in Digestive Medicine (APDW 2015 TAIPEI) (教育演講)(主持人),Taipei,2015.12.3 ~ 2015.12.6,Postgraduate Course Liver session: (主持人)
45﹒ Association between Pre-S2 Deletions and Virologic Rebound during Peginterferon Therapy in Patients with Hepatitis B E Antigen-Positive Chronic Hepatitis B,The AASLD LIVER MEETING 2015,SAN FRANCISCO/USA,2015.11.13 ~ 2015.11.17,
46﹒ ,TAIWAN-HEP B/C MASTER CLASS 2015 (教育演講)(主持人),Taichung,2015.10.25 ~ 2015.10.25,Management of HCV and HBV Infection in Taiwan)(主持人)
47﹒ Head-to-head Comparisons between Collagen Proportionate Area and Acoustic Radiation Force Impulse Elastography in Liver Fibrosis Evaluation,The Liver Week 2015,Busan, Republic of Korea,2015.9.10 ~ 2015.9.12,Head-to-head Comparisons between Collagen Proportionate Area and Acoustic Radiation Force Impulse Elastography in Liver Fibrosis Evaluation
48﹒ ,HCV Single Topic Conference Meeting Highlights,彰基國際培訓中心,2015.8.29 ~ 2015.8.29,The risk of deferral (debate)
49﹒ Recent Advance in Ultrasound-based Non-invasive Liver Fibrosis Evaluation,2015 TARFIT Learning and Sharing Workshop,高雄蓮潭會館,2015.7.18 ~ 2015.7.18,Recent Advance in Ultrasound-based Non-invasive Liver Fibrosis Evaluation
50﹒ ,2015 Post EASL&APASL Meeting (教育演講),台中,2015.5.24 ~ 2015.5.24,2015 Post EASL&APASL新知研討會
51﹒ Different Serum HBsAg Kinetics between Genotype B and C Both in HBeAg-Positive and -Negative Chronic Hepatitis B Patients Treated with Entecavir,中華民國一○四年消化系聯合學術演講年會,台北- 台大醫院國際會議中心,2015.3.28 ~ 2015.3.29,Different Serum HBsAg Kinetics between Genotype B and C Both in HBeAg-Positive and -Negative Chronic Hepatitis B Patients Treated with Entecavir
52﹒ Kinetics of Quantitative Serum HBsAg Decline During Seven Years of Nucleos(t)ide Analogue Therapy in Chronic Hepatitis B Patients,中華民國一○四年消化系聯合學術演講年會,台北- 台大醫院國際會議中心,2015.3.28 ~ 2015.3.29,Kinetics of Quantitative Serum HBsAg Decline During Seven Years of Nucleos(t)ide Analogue Therapy in Chronic Hepatitis B Patients
53﹒ Kinetics of Quantitative Serum HBsAg Decline During Seven Years of Nucleos(t)ide Analogue Therapy in Chronic Hepatitis B Patients,24th Conference of APASL 2015 ISTANBUL, Turkey,Istanbul/TURKEY,2015.3.12 ~ 2015.3.15,
54﹒ ,中華民國一○四年消化系聯合學術演講年會,台北- 台大醫院國際會議中心,2015.3.28 ~ 2015.3.29,TASL Consensus Statement on the Management of Chronic Hepatitis B
55﹒ ,Taiwan-HEP C MASTER CLASS 2014 (教育演講),Taichung,2014.11.30 ~ 2014.11.30,Management of HCV and HBV Infection in Taiwan
56﹒ Therapy of HBeAg Positive Patients,2014 Taiwan Digestive Disease Week,高雄展覽館,2014.10.3 ~ 2014.10.5,Personalized Therapy of HBV
57﹒ Current Status of HBV Treatment in Taiwan- Interferon Based,2014 Taiwan Digestive Disease Week,高雄展覽館,2014.10.3 ~ 2014.10.5,International Taiwan-Korea Forum of Viral Hepatitis
58﹒ Hepatitis B Free Paper,2014 Taiwan Digestive Disease Week,高雄展覽館,2014.10.3 ~ 2014.10.5,
59﹒ The pattern and predictors of serum HBsAg decline in chronic hepatitis B patients receiving up to five years of entecavir therapy,2014 Taiwan Digestive Disease Week,高雄展覽館,2014.10.3 ~ 2014.10.5,
60﹒ Decline in quantitative serum HBsAg level during consolidation therapy following HBeAg loss in HBeAg-positive chronic hepatitis B patients treated with entecavir,2014 Taiwan Digestive Disease Week,高雄展覽館,2014.10.3 ~ 2014.10.5,
61﹒ Sorafenib Combined with Transarterial Chemoembolization or Radiation Therapy Versus Sorafenib Alone For Advanced Stage Hepatocellular Carcinoma –A Daily Practice Analysis,8th Annual Conference of the International Liver Cancer Association (ILCA), 2014,Hotel Granvia Kyoto in Japan,2014.9.5 ~ 2014.9.7,
62﹒ ,2014 Single Topic Conference of Taiwan Association for the Study of the Liver (教育演講)-主持人,Taichung,2014.6.21 ~ 2014.6.22,Immunology and Chronic Viral Hepatitis / Alcohol and Non-Alcohol Related Liver Disease (主持人)
63﹒ ,2014 Post EASL&APASL Meeting (教育演講)-主持人,台中,2014.5.17 ~ 2014.5.17,2014 Post EASL&APASL新知研討會
64﹒ Predictors of Severe Hepatic Fibrosis in Treatment-Naïve Genotype B or C Infected E Antigen-Positive and -Negative Chronic Hepatitis B Patients,2014-The International Liver Congress,LONDON/UK,2014.4.9 ~ 2014.4.13,
65﹒ Association Between Genotype and Baseline HBsAg Levels and the HBsAg Levels at HBeAg Seroclearance in HBeAg-Positive Chronic Hepatitis B Patients Treated with Entecavir,2014-The International Liver Congress,LONDON/UK,2014.4.9 ~ 2014.4.13,
66﹒ Chronic Hepatitis B on Oral Nucleos(t)ide Analogue Therapy,中華民國103年台灣消化系聯合學術演講年會,臺南市國立成功大學,2014.3.8 ~ 2014.3.9,Case Scenario (Meet the Expert)
67﹒ Predictors of severe hepatic fibrosis in treatment-naive genotype B or C infected eAg-positive and -negative chronic hepatitis B patients,中華民國103年台灣消化系聯合學術演講年會,臺南市國立成功大學,2014.3.8 ~ 2014.3.9,
68﹒ Association between genotype and baseline HBsAg levels and the HBsAg levels at HBeAg seroclearance in HBeAg-positive chronic hepatitis B patients treated with entecavir,中華民國103年台灣消化系聯合學術演講年會,臺南市國立成功大學,2014.3.8 ~ 2014.3.9,
69﹒ Real-world experience of long-term ETV treatment in Taiwan,中華民國103年台灣消化系聯合學術演講年會,臺南市國立成功大學,2014.3.8 ~ 2014.3.9,What is the long-term treatment consideration in Taiwan chronic hepatitis B patients?
70﹒ Entecavir Real-World Data Update,中國附醫消化內科肝炎研討會,新天地璽悅時尚會館,2013.12.27 ~ 2013.12.27,Entecavir Real-World Data Update
71﹒ HBV Mutants During Antiviral Therapy,2013 Annual Conference of the Taiwan Association for the Study of the Liver,台南桂田酒店,2013.12.21 ~ 2013.12.22,
72﹒ Diagnostic index for advanced liver fibrosis in Asian chronic hepatitis B patients based on necroinflammation and liver stiffness measurement,The Liver Meeting 2013, AASLD,Washington, USA,2013.11.3 ~ 2013.11.4,Diagnostic index for advanced liver fibrosis in Asian chronic hepatitis B patients based on necroinflammation and liver stiffness measurement, published in Hepatology 2013; Special Issue: The Liver Meeting 2013; 58(S1):122A
73﹒ Predictive value of baseline and on-treatment quantitative serum HBsAg levels in therapeutic outcome to entecavir in patients with chronic hepatitis B.,The 64th Annual Meeting of the American Association for the Study of Liver Diseases,Washington, DC, USA,2013.11.1 ~ 2013.11.5,Predictive value of baseline and on-treatment quantitative serum HBsAg levels in therapeutic outcome to entecavir in patients with chronic hepatitis B.
74﹒ Taiwan Real-World Outcomes with NUC Therapy in CHB Management,中區肝炎專家學術研討會,日月潭大飯店,2013.11.16 ~ 2013.11.17,
75﹒ A Predictive Index using the Inosine Triphosphate Pyrophosphatase Gene Allele Status to Predict Ribavirin-induced Hemolytic Anemia in Genotype 1 Hepatitis C Virus-infected Asian Patients Receiving Pegylated Interferon and Ribavirin Combination Therapy,Taiwan Digestive Disease Week, 2013,Taipei, Taiwan,2013.10.4 ~ 2013.10.6,A Predictive Index using the Inosine Triphosphate Pyrophosphatase Gene Allele Status to Predict Ribavirin-induced Hemolytic Anemia in Genotype 1 Hepatitis C Virus-infected Asian Patients Receiving Pegylated Interferon and Ribavirin Combination Therapy
76﹒ Predictive Value of Baseline and On-Treatment Quantitative Serum HBsAg Levels in Therapeutic Outcome to Entecavir in Patients with Chronic Hepatitis B,2013 Taiwan Digestive Disease Week,台大醫院國際會議中心,2013.10.4 ~ 2013.10.6,
77﹒ Management of End-Stage Viral-Induced Liver Disease,肝炎學院,台中日月千禧酒店,2013.10.12 ~ 2013.10.12,Management of End-Stage Viral-Induced Liver Disease
78﹒ ARFI elastography 之臨床應用,中華民國醫用超音波學會2013 年第一次學術研討會,中國醫藥大學立夫教學大樓105 教室,2013.6.16 ~ 2013.6.16,ARFI elastography 之臨床應用
79﹒ Post-EASL and APASL Symposium,Post-EASL and APASL Symposium,台中日月千禧酒店,2013.6.16 ~ 2013.6.16,
80﹒ Update on Hepatitis B Reactivation due to Biological Agents,Management of Hepatitis B Reactivation in Special Patient Groups,台中清新溫泉飯店,2013.6.29 ~ 2013.6.30,
81﹒ Interim Analysis of Initial NUC Treatment Among NUC-naive Chronic Hepatitis B Patients in Taiwan,2013 APASL Liver Week,Singapore,2013.6.6 ~ 2013.6.10,
82﹒ Reactivation of Hepatitis B and C Viruses During Anticancer Therapy,中區婦癌學術研討會,彰濱秀傳紀念醫院,2013.5.18 ~ 2013.5.18,
83﹒ Predictive role of serum HBsAg level in genotype B or C HBeAg-negative chronic hepatitis B patients undergoing peginterferon therapy.,48th Annual Meeting of the European Association for the Study of the Liver,Amsterdam, the Netherlands,2013.4.24 ~ 2013.4.28,Predictive role of serum HBsAg level in genotype B or C HBeAg-negative chronic hepatitis B patients undergoing peginterferon therapy.
84﹒ Evaluation of Decompensated Cirrhosis using Acoustic Radiation Force Impulse Elastography: comparisons with Child-Pugh and model for end-stage liver disease scores,中華民國102年台灣消化系聯合學術演講年會,高雄醫學大學,2013.3.15 ~ 2013.3.17,Evaluation of Decompensated Cirrhosis using Acoustic Radiation Force Impulse Elastography: comparisons with Child-Pugh and model for end-stage liver disease scores
85﹒ Ultrasonography-based Methods for Non-invasive Diagnosis of Liver Cirrhosis,中華民國102年台灣消化系聯合學術演講年會,高雄醫學大學,2013.3.16 ~ 2013.3.17,Ultrasonography-based Methods for Non-invasive Diagnosis of Liver Cirrhosis
86﹒ B型肝炎口頭報告,中華民國102年台灣消化系聯合學術演講年會,高雄醫學大學,2013.3.16 ~ 2013.3.17,
87﹒ HBeAg-Positive Treatment? What to Start,Hepatitis B Training Train,台中亞緻大飯店,2013.3.23 ~ 2013.3.23,HBeAg-Positive Treatment? What to Start
88﹒ Predictive role of quantitative serum HBsAg level in HBeAg-negative chronic hepatitis B patients undergoing peginterferon therapy,中華民國102年台灣消化系聯合學術演講年會,高雄醫學大學,2013.3.16 ~ 2013.3.17,
89﹒ Recent Advances of NUC in HBV- New Knowledge in AASLD 2012,2012台灣肝臟研究學會年會週邊專題討論,高雄醫學大學,2012.12.22 ~ 2012.12.23,Recent Advances of NUC in HBV- New Knowledge in AASLD 2012
90﹒ Necroinflammatory effects on noninvasive liver stiffness measurement using acoustic radiation force impulse elastography in Asian patients with chronic hepatitis B,中華民國101年消化系聯合學術演講年會 Taiwan Digestive Disease Week,國防醫學中心,2012.10.5 ~ 2012.10.7,
91﹒ Risk of Primary Liver Cancer in Patients with Pyogenic Liver Abscess: A Population-base Cohort Study,2012 Taiean Digestive Disease Week, TDDW,台北市國防醫學中心,2012.10.6 ~ 2012.10.7,Risk of Primary Liver Cancer in Patients with Pyogenic Liver Abscess: A Population-base Cohort Study
92﹒ Predictors of Serum HBsAg Decline in Chronic Hepatitis B Patients Undergoing Entecavir Therapy,中華民國101年消化系聯合學術演講年會,台北國防醫學中心,2012.3.23 ~ 2012.3.25,Predictors of Serum HBsAg Decline in Chronic Hepatitis B Patients Undergoing Entecavir Therapy
93﹒ Complications of Radiofrequency Ablation Based Focal Therapies to Hepatic Tumors,中華民國101年消化系聯合學術演講年會,台北國防醫學中心,2012.3.23 ~ 2012.3.25,
94﹒ NONINVASIVE ASSESSMENT OF LIVER FIBROSIS VIA SPLEEN STIFFNESS MEASUREMENT USING ACOUSTIC RADIATION FORCE IMPULSE SONOELASTOGRAPHY IN PATIENTS WITH CHRONIC HEPATITIS B OR C,22nd Congress of the Asian Pacific Association for the Study of the Liver (APASL 2012),The Taipei International Convention Center,2012.2.17 ~ 2012.2.19,NONINVASIVE ASSESSMENT OF LIVER FIBROSIS VIA SPLEEN STIFFNESS MEASUREMENT USING ACOUSTIC RADIATION FORCE IMPULSE SONOELASTOGRAPHY IN PATIENTS WITH CHRONIC HEPATITIS B OR C
95﹒ RFA immediately after PEI for treating HCC might increase the risk of delayed pyogenic liver abscess,The 22nd Congress of the Asian Pacific Association for the Study of the Liver (APASL 2012),Taipei International Convention Center,2012.2.16 ~ 2012.2.19,
96﹒ Severe Liver Fibrosis in Patients with HCV Infection is Associated with Increased Risk of Chronic Kidney Disease,台灣腎臟醫學會 100年度會員大會暨學術演講會,國防醫學院3樓,2011.12.10 ~ 2011.12.11,
97﹒ Prevalence and Prevention of HBV Reactivation in Lymphoma Related Therapy,淋巴癌學術研討會,劍湖山王子大飯店,2011.11.19 ~ 2011.11.20,Prevalence and Prevention of HBV Reactivation in Lymphoma Related Therapy
98﹒ Predictors of Development of HBeAg-Negative Chronic Hepatitis B Following Peginterferon Alfa-2a Therapy in HBeAg-Positive Chronic Hepatitis B,The 62nd Annual Meeting of the American Association for the Study of Liver Diseases,San Francisco, CA, USA,2011.11.4 ~ 2011.11.8,Predictors of Development of HBeAg-Negative Chronic Hepatitis B Following Peginterferon Alfa-2a Therapy in HBeAg-Positive Chronic Hepatitis B
99﹒ 以聲脈衝幅射力技術預測C型肝炎病人肝纖維化分級之效度分析,Taiwan Digestive Disease Week (TDDW) 2011 中華民國100年消化系聯合學術演講年會,國防醫學中心,2011.10.7 ~ 2011.10.10,
100﹒ Insights From a Special Population: Chronic Hepatitis B Related Decompensated Liver Disease,Taiwan Digestive Disease Week (TDDW) 2011 中華民國100年消化系聯合學術演講年會衛星演講,台北喜來登酒店,2011.10.7 ~ 2011.10.7,Trouble-Free Management of Hepatitis B Patients
101﹒ Predictors of Development of HBeAg-Negative Chronic Hepatitis B Following Peginterferon Alfa-2a Therapy in HBeAg-Positive Chronic Hepatitis B,Taiwan Digestive Disease Week (TDDW) 2011 中華民國100年消化系聯合學術演講年會,國防醫學中心(台北市民權東路6段161號),2011.10.8 ~ 2011.10.10,Predictors of Development of HBeAg-Negative Chronic Hepatitis B Following Peginterferon Alfa-2a Therapy in HBeAg-Positive Chronic Hepatitis B
102﹒ Recent Advances of Nucleos(t)ide Analogues Therapy of Chronic Hepatitis B,Taiwan Digestive Disease Week (TDDW) 2011 中華民國100年消化系聯合學術演講年會,國防醫學中心(台北市民權東路6段161號),2011.10.8 ~ 2011.10.10,TASL Consensus Statement on the Management of Chronic Hepatitis B- A 2011 Update
103﹒ A Practical Guide to Using Virologic and Serologic Tests in the Management of Hepatitis B,2011中國附醫 肝炎治療研討會,英格曼鄉村花園,2011.9.17 ~ 2011.9.17,A Practical Guide to Using Virologic and Serologic Tests in the Management of Hepatitis B
104﹒ Simultaneous Liver and Kidney Transplantation From Different Living Donors,2011 12th Congress of The Asian Society of Transplantation,COEX,Seoul, Korea,2011.9.25 ~ 2011.9.28,
105﹒ ,中部地區B型肝炎治療聯合病歷討論會,台一生態園區會議室,2011.6.18 ~ 2011.6.18,The Update management for Chronic Hepatitis B
106﹒ Protecting the Future for Patients with Chronic Hepatitis B,2011 Single Topic Conference: TASL, Luncheon Symposium,高雄醫學大學一樓大講堂,2011.6.26 ~ 2011.6.26,Protecting the Future for Patients with Chronic Hepatitis B
107﹒ Evolution of Future Treatment Options for Chronic Hepatitis C,Post APASL/EASL Symposium,台中長榮桂冠酒店,2011.4.23 ~ 2011.4.23,
108﹒ Time Trends of Gastroesophageal Reflux Disease, Esophageal Cancer, Gastric Cancer, and Peptic Ulcer Disease in Taiwan 2000 to 2008 - a population based study,中華民國100年消化系聯合學術演講年會,國防醫學中心,2011.3.5 ~ 2011.3.6,
109﹒ ARE METABOLIC PARAMETERS ASSOCIATED WITH VIROLOGIC RESPONSE TO PEGINTERFERON ALFA PLUS RIBAVIRIN THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C:A SINGLE CENTER EXPERIENCE,中華民國100年臺灣消化系醫學會春季學術演講年會,臺北市內湖區國防醫學中心,2011.3.4 ~ 2011.3.5,
110﹒ 超音波導引經皮肝臟及肝腫塊穿刺切片之併發症:一醫學中心之六年報告,中華民國100年消化系聯合學術演講年會春季會,國防醫學中心,2011.3.5 ~ 2011.3.6,
111﹒ PREDICTORS OF THERAPEUTIC RESPONSE TO PEGINTERFERON ALFA-2A IN PATIENTS WITH HBeAg-POSITIVE CHRONIC HEPATITIS B,中華民國一00年消化系聯合學術演講年會,國防醫學中心(台北市民權東路6段161號),2011.3.5 ~ 2011.3.6,
112﹒ Therapy of Chronic Hepatitis B- CMUH Experience,臺灣消化系醫學會第四十一屆學術研討會春季會,國防醫學中心(台北市民權東路6段161號),2011.3.5 ~ 2011.3.6,與專家晤談: 慢性B型肝炎的治療: 從指引到實務
113﹒ Current Strategy for Chronic Hepatitis B Management: Baraclude Worldwide Real World Data Update,臺灣消化系醫學會第四十一屆學術研討會春季會週邊專題討論,台北喜來登酒店,2011.3.4 ~ 2011.3.4,Current Strategy for Chronic Hepatitis B Management: Baraclude Worldwide Real World Data Update
114﹒ 運用模糊理論來預測C型肝炎病人肝硬化的嚴重程度,中華民國一00年消化系聯合學術演講年會,國防醫學中心(台北市民權東路6段161號),2011.3.5 ~ 2011.3.6,
115﹒ MIRIZZI徵候群的治療經驗,中華民國一00年消化系聯合學術演講年會,國防醫學中心(台北市民權東路6段161號),2011.3.5 ~ 2011.3.6,
116﹒ 腸道症狀病患小腸憩室疾病盛行率之研究,中華民國一00年消化系聯合學術演講年會,國防醫學中心(台北市民權東路6段161號),2011.3.5 ~ 2011.3.6,
117﹒ 使用自膨式金屬支架緩解惡性食道狹窄或廔管:一個醫學中心的經驗,中華民國一00年消化系聯合學術演講年會,國防醫學中心(台北市民權東路6段161號),2011.3.5 ~ 2011.3.6,
118﹒ PEGYLATED INTERFERON-ASSOCIATED LIFE-THREATENING UPPER GASTROINTESTINAL BLEEDING IN UREMIC PATIENTS WITH CHRONIC HEPATITIS C,中華民國一00年消化系聯合學術演講年會,國防醫學中心(台北市民權東路6段161號),2011.3.5 ~ 2011.3.6,
119﹒ CLINICAL ANALYSIS OF PATIENTS WITH CELIAC ARTERY COMPRESSION SYNDROME:EXPERIENCE OF A MEDICAL CENTER IN MID-TAIWAN,中華民國一00年消化系聯合學術演講年會,台北喜來登飯店B2福祿廳,2011.3.4 ~ 2011.3.6,
120﹒ RISK FACTORS OF GALLSTONE PANCREATITIS IN PATIENTS WITH NON-ALCOHOLIC LIVER CIRRHOSIS,中華民國一00年消化系聯合學術演講年會,國防醫學中心(台北市民權東路6段161號),2011.3.5 ~ 2011.3.6,
121﹒ 2010 AASLD Highlight: new advances in treatment of chronic hepatitis B,Year 2010 Post-AASLD Symposium,臺中市福華大飯店,2010.11.27 ~ 2010.11.27,
122﹒ Serum alpha-fetoprotein level correlates with hepatic p21WAF/Cip1 expression in patients with chronic hepatitis C,The 61th Annual Meeting of the American Association for the Study of Liver Diseases,Boston, USA,2010.10.29 ~ 2010.11.2,
123﹒ ALT flares and their relation with HBeAg loss during peginterferonα-2A theapy in patients with HBeAg-positive chronic hepatitis B,中華民國九十九年臺灣消化系醫學會秋季學術演講年會,臺北市內湖區國防醫學中心,2010.10.1 ~ 2010.10.3,
124﹒ Kinetics of serum HBsAg and HBV DNA levels during peginterferon alfa-2A therapy in patients with HBeAg-positive chronic hepatitis B: genotype B versus C,中華民國九十九年臺灣消化系醫學會秋季學術演講年會,臺北市內湖區國防醫學中心,2010.10.1 ~ 2010.10.3,
125﹒ ALT Flares and Their Relation with HBeAg Loss during Peginterferon α-2a Therapy in Patients with HBeAg-Positive Chronic Hepatitis B,2010年秋季學術演講會,國防醫學中心,2010.10.2 ~ 2010.10.3,ALT Flares and Their Relation with HBeAg Loss during Peginterferon α-2a Therapy in Patients with HBeAg-Positive Chronic Hepatitis B
126﹒ Treatment of chronic hepatitis B with nucleos(t)ide analogues,台灣消化系醫學會第30屆教育研討會『肝臟疾病之診斷與治療』,台大醫學院102講堂,2010.9.5 ~ 2010.9.5,Treatment of chronic hepatitis B with nucleos(t)ide analogues
127﹒ A novel hepatitis C virus-induced protein modulates hepatic stellate cell activation through JNK signaling pathway,17th International Meeting on Hepatitis C Virus and Related Viruses,Japan yohohama,2010.9.10 ~ 2010.9.14,
128﹒ Hypovascular Liver Tumors with High Serum Alpha-fetoprotein in a Patient with Chronic Hepatitis B and Ascites,The 3rd Annual Meeting and International Liver Cancer Symposium of the Taiwan Liver Cancer Associati,Sheraton Taipei B2 Joyful ballroom,2010.7.25 ~ 2010.7.25,
129﹒ 2010 Beijing APASL and Vienna EASL HCV Note Highlight,Post-APASL/EASL Congress,臺中市日華金典酒店,2010.6.12 ~ 2010.6.12,
130﹒ A Patient with Hepatocellular Carcinoma which is Detectable with Ultrasonography but Isovascular on Dynamic CT scan,中華民國醫用超音波學會2010年第二次學術研討會,中國醫藥大學立夫教學大樓,2010.5.16 ~ 2010.5.16,
131﹒ 肝炎病毒檢驗及臨床之應用,2010年愛滋病及病毒性肝炎檢驗品質提升研討會,澄清醫院中港院區 十七樓國際會議廳,2010.5.23 ~ 2010.5.23,肝炎病毒檢驗及臨床之應用
132﹒ 彈性影像於肝臟疾病處置之應用,中華民國醫用超音波學會2010年第二次學術研討會,中國醫藥大學立夫教學大樓,2010.5.16 ~ 2010.5.16,
133﹒ The effects of polymorphisms in phospholipase a2 and cyclo-oxygenase 2 genes on interferon-alpha-induced depression and polyunsaturated fatty acids levels,The 9th International Society for the Study of Fatty Acids and Lipids (ISSFAL),Maastricht, The Netherlands,2010.5.29 ~ 2010.6.2,The effects of polymorphisms in phospholipase a2 and cyclo-oxygenase 2 genes on interferon-alpha-induced depression and polyunsaturated fatty acids levels
134﹒ Current Therapy of Chronic Hepatitis B,內科醫學會中部地區四月份地方月會,國軍台中總醫院醫療大樓三樓電化教室,2010.4.24 ~ 2010.4.24,Current Therapy of Chronic Hepatitis B
135﹒ Changes in Serum Triglyceride Levels in Patients with Chronic Hepatitis C and Patients with Chronic Hepatitis B Undergoing Peginterferon-Based Therapy:a single center experience,中華民國九十九年消化系聯合學術演講年會,國防醫學中心(台北市民權東路六段 161 號),2010.3.20 ~ 2010.3.21,Changes in Serum Triglyceride Levels in Patients with Chronic Hepatitis C and Patients with Chronic Hepatitis B Undergoing Peginterferon-Based Therapy: a single center experience
136﹒ 內視鏡黏膜切除術在上消化道黏膜病變之治療:一教學醫院之經驗,2010消化系聯合學術演講年會,三軍總醫院,2010.3.20 ~ 2010.3.21,
137﹒ C型肝炎患者於抗病毒藥物治療後達到病毒持續反應的預測因子,2010消化系聯合學術演講年會,三軍總醫院,2010.3.20 ~ 2010.3.21,
138﹒ 探尋評估慢性B型肝炎纖維化的非侵入性指標,尚待發掘的指標存在嗎?,2010消化系聯合學術演講年會,三軍總醫院,2010.3.20 ~ 2010.3.21,
139﹒ 長效型干擾素ALFA-2A在E抗原陽性之慢性B型肝炎療效分析,2010消化系聯合學術演講年會,三軍總醫院,2010.3.20 ~ 2010.3.21,
140﹒ 內視鏡超音波輔助下內視鏡治療乏特氏乳突腫瘤,2010消化系聯合學術演講年會,三軍總醫院,2010.3.20 ~ 2010.3.21,內視鏡超音波輔助下內視鏡治療乏特氏乳突腫瘤
141﹒ 以內視鏡支架置放治療胰臟炎引起的總膽管狹窄之療效,2010消化系聯合學術演講年會,三軍總醫院,2010.3.20 ~ 2010.3.21,
142﹒ Final results of ACHIEVE-2/3: albinterferon alfa-2b plus ribavirin in treatment-naïve patients with genotype 2/3 chronic hepatitis C,第20屆亞太肝病研究學會年會,中國北京市,2010.3.25 ~ 2010.3.28,
143﹒ EMR for the treatment of mucosal lesions in the upper GI tract: An experience in an academic medical,中華民國九十九年消化系聯合學術演講年會-台灣消化系醫學會暨台灣消化系內視鏡醫學會聯合學術演講年會,國學醫學中心,2010.3.19 ~ 2010.3.21,
144﹒ Acute gastric hyperplastic polyp,台灣消化系內視鏡醫學會第四十八次電子內視鏡病例討論會,中國醫藥大學附設醫院 第二醫療大樓11樓會議室,2010.1.23 ~ 2010.1.23,Acute gastric hyperplastic polyp
145﹒ DO DIABETES PATIENTS WITH KLEBSIELLA PNEUMONIAE LIVER ABSCESS NEED FURTHER EVALUATION OF THE COLON FOR PRESENCE OF NEOPLASM IN TAIWAN?,GASTRO 2009 UEGW/ WCOG,London,2009.11.21 ~ 2009.11.25,
146﹒ From Clinical Trials to Clinical Experience: Baraclude Update,Post-AASLD Congress,台中市長榮桂冠酒店,2009.11.21 ~ 2009.11.21,From Clinical Trials to Clinical Experience: Baraclude Update
147﹒ Early HBeAg Loss During Lamivudine Therapy in HBeAg-Positive Chronic Hepatitis B Patients with Acute Exacerbation,The 60th Annual Meeting of the American Association for the Study of Liver Diseases,Boston, USA,2009.10.30 ~ 2009.11.3,
148﹒ The Prevalence of Gallbladder Stones is higher among patients with higher degree of liver fibrosis,Asia Pacific digestive Week,Taipei International convention Center Taipei,Taiwan,2009.9.27 ~ 2009.9.30,
149﹒ Efficacy of entecavir in naive patients with chronic hepatitis B and decompensated liver cirrhosis,Asian Pacific Digestive Week,Taipei International Convention Center, Taipei, Taiwan,2009.9.27 ~ 2009.9.30,
150﹒ (Case discussion) Successful RFA with PEI to one 3.7 cm HCC at S6 tip high risk location,98年度中部地區台灣肝癌醫學教育研討會,彰化基督教醫院11樓連瑪玉講堂,2009.7.11 ~ 2009.7.11,(Case discussion) Successful RFA with PEI to one 3.7 cm HCC at S6 tip high risk location
151﹒ HBeAg-Negative Chronic Hepatitis B 使用 Pegasys 治療經驗之分享,北中區聯合肝癌學術研討會,泰安觀止,2009.5.2 ~ 2009.5.3,HBeAg-Negative Chronic Hepatitis B 使用 Pegasys 治療經驗之分享
152﹒ Polyunsaturated fatty acids and interferon-alpha-induced depression,Polyunsaturated fatty acids and interferon-alpha-induced depression,Vancouver, Canada,2009.5.14 ~ 2009.5.16,Polyunsaturated fatty acids and interferon-alpha-induced depression
153﹒ PEGYLATED INTERFERON α-2A THERAPY FOR HBEAG-NEGATIVE CHRONIC HEPATITIS B,中華民國九十八年消化系聯合學術演講年會,台北醫學大學附設醫院,2009.3.14 ~ 2009.3.15,PEGYLATED INTERFERON α-2A THERAPY FOR HBEAG-NEGATIVE CHRONIC HEPATITIS B
154﹒ Evaluation of endoscopic ligation for the treatment of small EUS-suspected gastric gastrointestinal stromal tumors,2009 台灣消化系聯合學術演講年會,台北,2009.3.13 ~ 2009.3.15,
155﹒ Clinical Analysis of Gastric Lymphoma: Experience of a Medical Center in Taiwan,2009 台灣消化系聯合學術演講年會,台北醫學大學,2009.3.13 ~ 2009.3.15,
156﹒ Peginterferon Alfa and Ribavirin Therapy for 24 versus 48 Weeks in Chronic Hepatitis C Genotype 1 Patients,台灣消化系醫學會 台灣消化系內視鏡醫學會2009年聯合學術演講年會,台北醫學大學,2009.3.14 ~ 2009.3.15,
157﹒ 經内視鏡超音波診斷之上消化道脂肪瘤臨床分析,2009台灣消化系醫學會春季聯合學術演講年會,台北,2009.3.13 ~ 2009.3.15,
158﹒ 經內視鏡超音波診斷上之消化道脂肪瘤臨床分析,2009年聯合學術演講年會,台北醫學大學,2009.3.14 ~ 2009.3.15,
159﹒ Polyunsaturated fatty acids and interferon-alpha-induced depression.,The Annual Meeting of British Association for Psychopharmacology (BAP),Harrogate, UK,2008.7.20 ~ 2008.7.23,
160﹒ Gastric GIST-Report of a Case,台灣消化系醫學會97年中部地區消化系同好會,彰化基督教醫院,2008.4.3 ~ 2008.4.3,
161﹒ 膽汁漏 之臨床分析:一個醫學中心的經驗 CLINICAL ANALYSIS OF BILE LEAK-AN EXPERIENCE IN A MEDICAL CENTER,中華民國九十七年消化系聯合學術演講年會春季會,國防醫學中心,2008.3.15 ~ 2008.3.16,
162﹒ 比較24週及48週長效型干擾素合併雷巴威林治療慢性C型肝炎患者對甲狀腺功能的影響,中華民國九十七年消化系聯合學術演講年會春季會,台北國防醫學中心,2008.3.15 ~ 2008.3.16,
163﹒ The Difference in the Chemotherapy Induced Hepatitis between HBV Infection and Non-HBV Infection in Lymphoma Patients,The 18th Conference of the Asian Pacific Association for the Study of the Liver,Seoul, Korea,2008.3.23 ~ 2008.3.26,
164﹒ Cellular mechanism of elevated serum alpha-fetoprotein levels in patients with chronic hepatitis C,中華民國九十七年消化系聯合學術演講年會,國防醫學中心,2008.3.14 ~ 2008.3.16,
165﹒ 不明原因之急性胰臟炎病人膽汁微結晶分析的臨床意義,中華民國九十七年消化系聯合學術演講年會,台北,2008.3.14 ~ 2008.3.16,
166﹒ THE CLINICAL ANALYSIS OF CHOLANGITIS- THE EXPERIENCE OF THE MEDICAL CENTER IN MIDDLE TAIWAN,台灣消化系醫學會2008年春季學術演講會,台北,2008.3.15 ~ 2008.3.16,
167﹒ 經皮內視鏡胃造口術應用於癌症病患之臨床經驗:壹醫學中心的經驗,中華民國九十七年消化系聯合學術演講年會,台北國防醫學中心,2008.3.14 ~ 2008.3.16,
168﹒ Clinical Experience of Endoscopic Management of Acute Upper Gastrointestinal Bleeding Related to Dieulafoy's Lesion,中華民國九十七年消化系聯合學術演講年會台灣消化系醫學會(第三十八屆)台灣消化系內視鏡醫學會(第十七次)聯合學術演講年會,國防醫學中心,2008.3.14 ~ 2008.3.16,
169﹒ Afferent loop syndrome,97年1月份中區消化系同好會,台中,2008.1.3 ~ 2008.1.3,
170﹒ Gastric signet ring cell carcinoma with metastasis to rectum- report of a rare case,台灣消化系醫學會九十六年中部地區消化系同好會,中山醫學大學(文心南路99號),2007.12.6 ~ 2007.12.6,Gastric signet ring cell carcinoma with metastasis to rectum- report of a rare case
171﹒ IPMN(Intraductal Papillary Mucinous Neoplasm): report of a case,台灣消化系醫學會第二二二次學術討論月會,財團法人長庚紀念醫院 高雄分院,2007.11.17 ~ 2007.11.17,IPMN(Intraductal Papillary Mucinous Neoplasm): report of a case
172﹒ Polymorphisms in cytosolic phospholipase A2 and cyclooxygenase 2 genes and risk of interferon-induced depression.,The 20th European College Neuropsychopharmacology,Vienna, Austria.,2007.10.14 ~ 2007.10.17,
173﹒ Cronkhite-Canada Syndrome- Report of a Case,台灣消化系內視鏡醫學會第42次電子內視鏡病例討論會,台中榮民總醫院,2007.10.20 ~ 2007.10.20,Cronkhite-Canada Syndrome- Report of a Case
174﹒ 73歲先生,主訴上腹痛併轉移至背部,病史為慢性C型肝炎併左葉肝癌,接受4次酒精注射,第42次電子內視鏡病例討論會,台中榮民總醫院,2007.10.20 ~ 2007.10.20,
175﹒ The Differen in the Chemotherapy Induced Heaptitis Between HBV Carrier and Non-HBV Carrier in Cancer Patients,2007 Autumn Convention,國防醫學中心,2007.9.29 ~ 2007.9.30,
176﹒ Accuracy of endoscopic ultrasonography in diagnosing upper gastrointestinal subepithelial tumors: a single center experience,2007年台灣消化系醫學會秋季學術演講年會,台北,2007.9.29 ~ 2007.9.30,
177﹒ 男性安非他命成癮者病毒性肝炎之研究(Viral Hepatitis among Male Amphetamine-inhaling Abusers),台灣家庭醫學醫學會九十六年度學術研討會,台北國防醫學院,2007.7.15 ~ 2007.7.15,
178﹒ Tuberculous Peritonitis & Colitis – Report of a Case,台灣消化系醫學會九十六年中部地區消化系同好會,慈濟醫院台中分院,2007.7.5 ~ 2007.7.5,Tuberculous Peritonitis & Colitis – Report of a Case
179﹒ Polymorphisms in cytosolic phospholipase A2 and cyclooxygenase 2 Genes and risk of interferon-induced depression.,The 61st annual meeting of the Society of Biological Psychiatry Association,San Diego, California, U.S.A.,2007.5.17 ~ 2007.5.19,
180﹒ 以內視鏡超音波診斷異位性胰臟之臨床分析:一個醫學中心的經驗Clinical Analysis of Ectopic Pancreas with Endoscopic Ultrasound(EUS)-The Experience in a Medical Center,消化系醫學會2007春季會,中華民國高雄/台北,2007.3 ~ ,
181﹒ The transmission route of Viral Hepatitis C and HIV is changing in Taiwan,Official Journal of Asian Pacific Association for the Study of the Liver,日本日本,2007.3 ~ ,
182﹒ 比較內視鏡膽管切片、刷拭細胞學檢查及膽汁細胞學檢查以診斷惡性膽管狹窄之前瞻性研究,中華民國九十六年消化系聯合學術演講年會,台灣高雄縣,2007.3 ~ ,
183﹒ The Route of HCV and HIV Transmission Changing in Present,中華民國九十六年消化系聯合學術演講年會,高雄縣勞工育樂中心,2007.3.16 ~ 2007.3.18,
184﹒ Diagnostic Role of Des-γ-Car-Boxy Prothrombin and Glypican-3 in Hepatocellular Carcinoma,中華民國九十六年消化系聯合學術演講年會,高雄縣勞工育樂中心,2007.3.16 ~ 2007.3.18,
185﹒ 上消化道上皮下腫瘤在內視鏡超音波下的表現探討,台灣消化系醫學會2007年春季學術演講會,高雄,2007.3.17 ~ 2007.3.18,
186﹒ A prospective study of comparing endobiliary biopsies, brush cytology, and bile cytology for diagnosing malignant biliary stricture,中華民國九十六年消化系聯合學術演講年會,台灣高雄,2007.3.16 ~ 2007.3.18,A prospective study of comparing endobiliary biopsies, brush cytology, and bile cytology for diagnosing malignant biliary stricture
187﹒ 膠囊內視鏡應用在診斷不明性胃腸道出血之臨床經驗:壹醫學中心的經驗,中華民國九十六消化系聯合學術演講春季年會,台灣高雄縣,2007.3.17 ~ 2007.3.18,
188﹒ MICROSCOPIC COLITIS 之中臺灣臨床經驗,2007春季消化系年會,台北,2007.3.17 ~ 2007.3.18,
189﹒ Diagnnostic Role of Des-r-carcoxy Prothrombin and Glypican-3 in Hepatocellular Carcinoma,消化系醫學會春季會,高雄長庚,2007.3.17 ~ 2007.3.18,
190﹒ Recurrent gastric hyperplastic polyps: a case report with review of association with COX-2 expression,台灣消化系醫學會第二一九次學術討論月會,中國醫藥大學附設醫院第二醫療大樓11樓會議室,2007.1.20 ~ 2007.1.20,Recurrent gastric hyperplastic polyps: a case report with review of association with COX-2 expression
191﹒ Ectopic pancreas: a case report with review of 33 cases,台灣消化系醫學會第二一九次學術討論月會,中國醫藥大學附設醫院第二醫療大樓11樓會議室,2007.1.20 ~ 2007.1.20,Ectopic pancreas: a case report with review of 33 cases
192﹒ CASE REPORT: Mirizzi syndrome,台灣消化系醫學會第二一九次學術討論月會,中國醫藥大學 附設醫院第二醫療大樓,2007.1.20 ~ 2007.1.20,
193﹒ Effect of impacted ampulary stones on the severity of gallstone diseases,21st International Workshop on Therapeutic Endoscopy,中國香港,2006.12.12 ~ 2006.12.14,
194﹒ Predisposing factors of streptococcus bovis bacteremia: the role of chronic liver disease in taiwan,歐洲消化系醫學會,德國柏林,2006.10 ~ ,
195﹒ Microarray analysis of hbv-related early human hepatocellular carcinoma,2006年台灣消化系醫學會秋季會,台灣台北市,2006.9 ~ ,
196﹒ New route of virus hepatitis c and hiv transmission,Internation Association for the Study of the Liver and the African Association for the Study of Live,埃及開羅,2006.9 ~ ,
197﹒ HBV reactivated post chemotherapy,台灣消化系醫學會第二一六次學術討論月會,台灣彰化,2006.4 ~ ,
198﹒ HBV reactivated post chemotherapy,台灣消化系醫學會第216次學術討論月會,彰化基督教醫院,2006.4.22 ~ 2006.4.22,
199﹒ Clinical analysis of upper gastrointestinal bezoar: experience of a medical center in middle Taiwan,中華民國九十五年消化系聯合學術演講年會,台灣台南,2006.3 ~ ,
200﹒ The prevalence and clinical assessment of HBV and HCV infection in HIV infection patients,中華民國九十五年消化系聯合學術演講年會,台灣台南,2006.3 ~ ,
201﹒ The prevalence rate and clinic assessment of hbv and hcv in addictive drugs abuser,中華民國九十五年消化系聯合學術演講年會,台灣台南,2006.3 ~ ,
202﹒ CLINICAL SIGNIFICANCY OF URINARY 8-HYDROXY-2’-DEOXYGU-ANOSINE RELATED TO NON-ALCOHOLIC FATTY LIVER DISEASE IN TAIWAN-PRELIMINARY REPORT ,中華民國九十五年消化系聯合學術演講年會,台灣台南,2006.3 ~ ,
203﹒ 上腸繫膜動脈症候群的臨床分析:壹醫學中心的經驗,中華民國九十五年消化系聯合學術演講春季年會,台灣台南市,2006.3.18 ~ 2006.3.19,
204﹒ Phlebosclerosis with calcification complicated with ischemic colitis case report,台灣消化系內視鏡醫學會第三十七次電子內視鏡病例討論會,Taiwan高雄,2006.2 ~ ,
205﹒ 62 y/o female patient suffered from abdominal fullness, fever, nausea, RLQ pain and no stool passage for 2 days,第37次電子內視鏡病例討論會,高雄,2006.2.25 ~ 2006.2.25,
206﹒ A rare huge lower abdoment mass--- One case report,2006 二月份中區消化系同好會,台中全國飯店,2006.2.9 ~ 2006.2.9,
207﹒ Ischemic Colitis Caused by Phlebosclerosis with Calcification: Report of a Case,台灣消化系醫學會第二一五次學術討論月會,台灣台北,2005.11 ~ ,
208﹒ The prevalence rate and clinic assessment of HBV and HCV in addictive drugs abuser,2005 Taipei Forum of Gastroenterology,台灣台北,2005.10 ~ ,
209﹒ Ectopic Pancreas: A Case Report,台灣消化系內視鏡醫學會第36次電子內視鏡病例討論會,台灣台中,2005.10 ~ ,
210﹒ Infrared spectroscopic analysis of billary microcrystal in diagnosing composition of choledocholithiasis,World Congress of Gastroenterology,加拿大蒙特婁,2005.9 ~ ,
211﹒ Infrared spectroscopic analysis of biliary microcrystals in diagnosing composition of choledocholithiasis,Word Congress of Gastroenterology,Montreal, Canada,2005.9.9 ~ 2005.9.14,
212﹒ 多型性CYP2C19基因型鑑定方法對OMEPRAZOLE治療GERD病患研究,中華民國九十四年台灣消化系聯合學術演講年會,台灣台北,2005.3 ~ ,
213﹒ 心膿性肝膿瘍是潛在大腸腺瘤及腺癌的一個警告指標,94年消化系聯合會,台灣台北,2005.3.19 ~ 2005.3.19,
214﹒ Analysis of biliary microcrystal in predicting composition of bile duct stones,中華民國九十四年消化系聯合學術演講年會,台北,2005.3.11 ~ 2005.3.13,Analysis of biliary microcrystal in predicting composition of bile duct stones
215﹒ A part of tumor syndromes-29.1% gastrointrstinal stromal tumor with other previous or concomitant neoplasm,Asia-Pacific Congress on Gastrointestinal Malignancies in Conjuction with the 8th Annual Meeting of,台灣台北,2004.12 ~ ,
216﹒ A part of tumor syndromes-29.1% gastrointrstinal stromal tumor with other previous or concomitant neoplasm,Asia-Pacific Congress on Gastrointestinal Malignancies,台灣台北,2004.12 ~ ,
217﹒ The Clinical Effectiveness of Plasmapheresis in Acute and Chronic Hepatic Failure,消化系醫學會春季研究會,台灣台北,2004.12 ~ ,
218﹒ Genotyping and mucoviscosity analysis of intra-cluster klebsiella pneumoniae isolated from liver abscess patients,The Gastroenterological Society of Taiwan 2004 Autumn Convention,台灣高雄,2004.9 ~ ,
219﹒ GENOTYPING AND MUCOVISCOSITY ANALYSIS OF INTRA-CLUSTER KLEBSIELLA PNEUMONIAE ISOLATED FROM LIVER ABSCESS PATIENTS,臺灣消化系醫學會 2004年秋季學術演講年會,台灣高雄,2004.9 ~ ,
220﹒ Genotyping and mucoviscosity analysis of intra-cluster klebsiella pneumoniae isolated from liver abscess patients,臺灣消化系醫學會2004 Autumn Convention & The 14th International Symposium,台灣高雄,2004.9 ~ ,
221﹒ The Clinical effectiveness of plasmaphoresis with anti-virus agent in Patients with virus induced acute hepatic failure,The 14th International Symposium of The Gastroenterological Society of Taiwan,台灣高雄,2004.9 ~ ,
222﹒ Clinical analysis of gastrointestinal stromal tumor: experience of a medical center,中華民國93年消化系聯合學術演講年會,台北,2004.3 ~ ,
 
研究計畫/Research Grant
(研究類型,研究計畫代號,主持人,補助或委託單位名稱,計畫名稱,研究經費,計畫期間)
1﹒ 個別型,MOST 104-2628-B-039 -001 -MY4,馬文隆(Wen-Lung Ma),賴學洲(Hsueh-Chou Lai)、彭成元(Cheng-Yuan Peng),科技部,肝癌治療的轉譯研究:從男性激素受體訊息基礎研究到發展具潛力臨床治療之評估,$1479000,2018.8.1 ~ 2019.7.31
2﹒ 個別型,MOST 104-2628-B-039 -001 -MY4,馬文隆(Wen-Lung Ma),賴學洲(Hsueh-Chou Lai)、彭成元(Cheng-Yuan Peng),科技部,肝癌治療的轉譯研究:從男性激素受體訊息基礎研究到發展具潛力臨床治療之評估,$1479000,2017.8.1 ~ 2018.7.31
3﹒ 國家型,A1051121,周德陽(Der-Yang Cho),趙坤山(Kun-San Chao)、邱昌芳(Chang-Fang Chiu)、蔡銘修(Ming-Hsui Tsai)、彭成元(Cheng-Yuan Peng)、夏德椿(Te-Chun Hsia)、陳自諒(William Tzu-Liang Chen)、洪耀欽(Yao-Ching Hung)、方信元(Hsin-Yuan Fang)、楊美都(Mei-Due Yang)、葉士芃(Su-Peng Yeh)、劉良智(Liu, Liang-Chih)、張兆祥(Chang,Chao-Hsiang)、柯道維(TAO-WEI KE)、葉聯舜(Lian-Shung Yeh)、梁基安(Ji-An Liang)、林文元(Wen-Yuan Lin)、王約翰(John Wang)、謝右文(Yow-Wen Hsieh)、蔡麗雲(Li-Yun Tsai)、謝淑惠(Shwn-Huey Shieh)、廖惠娟(Hui-Chuan Liao)、孟乃欣(Nai-Hsin Meng)、花俊宏(Chun-Hung Hua)、楊啟瑞(Che-Rei Yang)、徐華穗(Hua-Shai Hsu)、詹佳穎(Chia-Ing Jan)、蔡伯邦(Po-Pang Tsai)、林昭君(Chao-Chun Lin)、吳博倫(Po-Lun Wu)、謝清昀(Ching-Yun Hsieh)、簡君儒(Chun-Ru Chien)、楊世能(Shih-Neng Yang)、白禮源(Li-Yuan Bai),衛福部,106醫院癌症診療品質精進計畫,$11540000,2017.1.1 ~ 2017.12.31
4﹒ 臨床試驗與研究計畫,CMUH105-REC1-141,彭成元(Peng, Cheng-Yuan),賴學洲(Lai, Hsueh-Chou)、蘇文邦(Wen-Pang Su)、陳昇弘(Chen, Sheng-Hung)、陳景祥、王鴻偉(Hung-Wei Wang)、許偉帆(Wei-Fan Hsu),附醫廠商計畫,評估單一遞增劑量與多重劑量GSK3389404使用於慢性B型肝炎受試者之安全性、耐受性、藥動學與藥效學的一項雙盲、安慰劑對照試驗,$3627244,2017.1.1 ~ 2017.12.31
5﹒ 臨床試驗與研究計畫,CMUH106-REC2-016,彭成元(Peng, Cheng-Yuan),賴學洲(Lai, Hsueh-Chou)、蘇文邦(Wen-Pang Su)、王鴻偉(Hung-Wei Wang)、許偉帆(Wei-Fan Hsu)、陳昇弘(Chen, Sheng-Hung)、陳景祥,附醫廠商計畫,探討12週daclatasvir/asunaprevir合併ribavirin對C型肝炎病毒基因型1b無NS5A病毒突變株患者治療療效與安全性研究,$11330,2017.1.1 ~ 2017.12.31
6﹒ 臨床試驗與研究計畫,CMUH105-REC3-082,彭成元(Peng, Cheng-Yuan),賴學洲(Lai, Hsueh-Chou)、蘇文邦(Wen-Pang Su)、陳景祥、陳昇弘(Chen, Sheng-Hung),附醫廠商計畫,以Paritaprevir/Ritonavir/Ombitasvir 合併Dasabuvir 治療先前未曾接受治療以及曾接受治療慢性C 型肝炎病毒(HCV)基因亞型1b 感染且非肝硬化的血液透析患者,$9407,2017.1.1 ~ 2017.12.31
7﹒ 臨床試驗與研究計畫,CMUH106-REC3-054,邱昌芳(Chiu, Chang-Fang),彭成元(Peng, Cheng-Yuan)、賴學洲(Lai, Hsueh-Chou)、蘇文邦(Wen-Pang Su)、莊伯恒(Po-Heng Chuang)、王鴻偉(Hung-Wei Wang)、陳景祥、陳昇弘(Chen, Sheng-Hung)、許偉帆(Wei-Fan Hsu),附醫廠商計畫,針對先前接受全身性治療的晚期肝細胞癌亞洲受試者,比較Pembrolizumab併用最佳支持性照護相對於安慰劑併用最佳支持性照護,作為第二線療法的一項隨機分配、雙盲第三期試驗(KEYNOTE-394),$1288506,2017.1.1 ~ 2017.12.31
8﹒ 臨床試驗與研究計畫,CMUH106-REC1-069,彭成元(Peng, Cheng-Yuan),賴學洲(Lai, Hsueh-Chou)、莊伯恒(Po-Heng Chuang)、蘇文邦(Wen-Pang Su)、陳昇弘(Chen, Sheng-Hung)、陳景祥、許偉凡、王鴻偉(Hung-Wei Wang),附醫廠商計畫,一項第三期、隨機分配、雙盲、安慰劑對照試驗,在患有非酒精性脂肪肝(NASH)和橋接(F3)纖維化的受試者中,評估 Selonsertib 的安全性和療效,$2387826,2017.1.1 ~ 2017.12.31
9﹒ 臨床試驗與研究計畫,CMUH106-REC2-060,白禮源(Bai, Li-Yuan),邱昌芳(Chiu, Chang-Fang)、林振源(Chen-Yuan Lin)、連銘渝(Ming-Yu Lein)、彭成元(Peng, Cheng-Yuan)、賴學洲(Lai, Hsueh-Chou),附醫廠商計畫,針對 ATEZOLIZUMAB(抗 PD-L1 抗體)與 BEVACIZUMAB 和/或其他治療方式併用於實體瘤患者時的安全性與耐受性所做的開放標記、多中心、第 1b 期試驗,$14204248,2017.1.1 ~ 2017.12.31
10﹒ 臨床試驗與研究計畫,CMUH106-REC2-108,彭成元(Peng, Cheng-Yuan),賴學洲(Lai, Hsueh-Chou)、莊伯恒(Po-Heng Chuang)、蘇文邦(Wen-Pang Su)、陳景祥、陳昇弘(Chen, Sheng-Hung)、許偉凡、王鴻偉(Hung-Wei Wang),附醫廠商計畫,評估LJN452使用於非酒精性脂肪性肝炎(NASH)病患之安全性、耐受性與療效的一項隨機分配、雙盲、安慰劑對照、兩階段、適應性設計、多中心的12週試驗,$1559259,2017.1.1 ~ 2017.12.31
11﹒ 臨床試驗與研究計畫,CMUH106-REC3-101,彭成元(Peng, Cheng-Yuan),賴學洲(Lai, Hsueh-Chou)、蘇文邦(Wen-Pang Su)、陳昇弘(Chen, Sheng-Hung)、陳浤燿(Chen, Ching-Hsiang)、許偉帆(Wei-Fan Hsu)、王鴻偉(Hung-Wei Wang),附醫廠商計畫,針對感染慢性C型肝炎病毒(HCV)基因型1、2、4、5 或6 型且具有代償性肝硬化而未接受過治療的成人評估Glecaprevir (GLE)/Pibrentasvir (PIB)的療效與安全性的一項單組、開放性試驗,$1776605,2017.1.1 ~ 2017.12.31
12﹒ 臨床試驗與研究計畫,CMUH106-REC2-070,彭成元(Peng, Cheng-Yuan),賴學洲(Lai, Hsueh-Chou)、蘇文邦(Wen-Pang Su)、陳昇弘(Chen, Sheng-Hung)、陳景祥、許偉帆(Wei-Fan Hsu)、王鴻偉(Hung-Wei Wang),附醫廠商計畫,一項第 2 期、多中心、開放標示試驗,在患有基因型1、4、5、6 慢性C型肝炎感染且接受透析治療的末期腎病受試者中,評估Ledipasvir/Sofosbuvir 的療效及安全性,$1088647,2017.1.1 ~ 2017.12.31
13﹒ 臨床試驗與研究計畫,CMUH104-REC2-136,彭成元(Peng, Cheng-Yuan),賴學洲(Lai, Hsueh-Chou)、蘇文邦(Wen-Pang Su)、陳昇弘(Chen, Sheng-Hung)、陳景祥,附醫廠商計畫,一項隨機分配、開放性、多國多中心,用以評估ABT-493/ABT-530治療慢性C型肝炎病毒基因型第1型之成人病患之療效與安全性之臨床試驗 (ENDURANCE-1),$2669360,2017.1.1 ~ 2017.12.31
14﹒ 臨床試驗與研究計畫,CMUH104-REC2-023,彭成元(Peng, Cheng-Yuan),賴學洲(Lai, Hsueh-Chou)、蘇文邦(Wen-Pang Su)、陳昇弘(Chen, Sheng-Hung),附醫廠商計畫,一項長期追蹤研究,評估先前臨床試驗中已接受MK-5172治療之慢性C型肝炎受試者,其持續病毒反應和/或病毒抗藥性模式,$3926909,2017.1.1 ~ 2017.12.31
15﹒ 臨床試驗與研究計畫,CMUH102-REC1-089,彭成元(Peng, Cheng-Yuan),附醫廠商計畫,一項第三期、隨機、雙盲試驗,評估一日一次25毫克Tenofovir Alafenamide (TAF)療法治療B型肝炎e抗原陽性之慢性B型肝炎時的安全性及療效,並與一日一次300毫克Tenofovir Disoproxil Fumarate(TDF)療法進行比較,$4391939,2017.1.1 ~ 2017.12.31
16﹒ 臨床試驗與研究計畫,CMUH104-REC1-018,彭成元(Peng, Cheng-Yuan),賴學洲(Lai, Hsueh-Chou)、蘇文邦(Wen-Pang Su)、陳昇弘(Chen, Sheng-Hung)、陳景祥,附醫廠商計畫,一項橫斷生物標記試驗,針對以干擾素治療成功並認定為長期反應者的B型肝炎病毒感染病患,找出新的反應決定因子。,$2011891,2017.1.1 ~ 2017.12.31
17﹒ 臨床試驗與研究計畫,CMUH104-REC2-146,彭成元(Peng, Cheng-Yuan),賴學洲(Lai, Hsueh-Chou)、蘇文邦(Wen-Pang Su)、陳昇弘(Chen, Sheng-Hung)、陳景祥,附醫廠商計畫,一項對同時受到第 1 或 2 基因型 C 型肝炎病毒 (HCV) 與 B 型肝炎病毒 (HBV) 慢性感染的受試者,施用 Ledipasvir/Sofosbuvir 固定劑量複方劑 12 週的第 3b 期開放標示研究,$1829607,2017.1.1 ~ 2017.12.31
18﹒ 臨床試驗與研究計畫,CMUH104-REC1-002,彭成元(Peng, Cheng-Yuan),賴學洲(Lai, Hsueh-Chou)、蘇文邦(Wen-Pang Su)、陳昇弘(Chen, Sheng-Hung)、陳景祥,附醫廠商計畫,針對接受直接抗病毒藥物的B型肝炎病毒病患,找出新的反應決定因素的一項前瞻性生物標記試驗。,$3921864,2017.1.1 ~ 2017.12.31
19﹒ 臨床試驗與研究計畫,CMUH104-REC1-112,彭成元(Peng, Cheng-Yuan),賴學洲(Lai, Hsueh-Chou)、蘇文邦(Wen-Pang Su)、陳昇弘(Chen, Sheng-Hung)、陳景祥,附醫廠商計畫,一項隨機分配、雙盲、安慰劑對照、多國多中心,用以評估ABT-493/ABT-530治療慢性C型肝炎病毒基因型第2型之成人病患之療效與安全性之臨床試驗 (ENDURANCE-2),$3837222,2017.1.1 ~ 2017.12.31
20﹒ 臨床試驗與研究計畫,CMUH104-REC2-097,彭成元(Peng, Cheng-Yuan),賴學洲(Lai, Hsueh-Chou)、蘇文邦(Wen-Pang Su)、陳昇弘(Chen, Sheng-Hung)、陳景祥,附醫廠商計畫,一項開放性試驗,用以評估ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267)以及ABT-333併用Ribavirin (RBV)對於未曾接受治療及曾接受治療、慢性C型肝炎病毒(HCV)基因亞型1b感染且有代償性肝硬化之亞洲成人的安全性及療效,$3935048,2017.1.1 ~ 2017.12.31
21﹒ 臨床試驗與研究計畫,CMUH102-REC1-127,鄭隆賓(Jeng, Long-Bin),莊伯恒(Po-Heng Chuang)、陳永芳(Chen, Yung-Fang)、彭成元(Peng, Cheng-Yuan)、楊宏仁(Yang, Horng-Ren),附醫廠商計畫,第三期、安慰劑對照、多國多中心、隨機分配、雙盲試驗,評估K-333 (peretinoin)用於亞洲肝癌完全治癒受試者之療效及安全性,$7400299,2017.1.1 ~ 2017.12.31
22﹒ 臨床試驗與研究計畫,CMUH105-REC2-042,彭成元(Peng, Cheng-Yuan),邱昌芳(Chiu, Chang-Fang)、蘇文邦(Wen-Pang Su)、陳昇弘(Chen, Sheng-Hung)、陳景祥、莊伯恒(Po-Heng Chuang)、賴學洲(Lai, Hsueh-Chou),附醫廠商計畫,一項隨機、多中心、第III期試驗,以Nivolumab與Sorafenib對照做為晚期肝癌患者的第一線治療,$3284462,2017.1.1 ~ 2017.12.31
23﹒ 臨床試驗與研究計畫,CMUH105-REC1-102,邱昌芳(Chiu, Chang-Fang),彭成元(Peng, Cheng-Yuan)、賴學洲(Lai, Hsueh-Chou)、蘇文邦(Wen-Pang Su)、莊伯恒(Po-Heng Chuang)、王鴻偉(Hung-Wei Wang)、陳景祥、陳昇弘(Chen, Sheng-Hung),附醫廠商計畫,針對先前接受全身性治療的晚期肝細胞癌受試者,比較Pembrolizumab (MK-3475)與最佳支持性照護作為第二線療法的一項第三期試驗(KEYNOTE-240),$2155308,2017.1.1 ~ 2017.12.31
24﹒ 臨床試驗與研究計畫,DMR101-IRB1-121,彭成元(Peng, Cheng-Yuan),附醫廠商計畫,評估P1101對於未接受干擾素治療之感染慢性B型肝炎病毒患者的抗病毒活性、安全性與藥物動力學之開放性、隨機分配、有效藥對照、劑量探索的臨床I/II期試驗(計劃書編號:A12-201),$1856107,2017.1.1 ~ 2017.12.31
25﹒ 臨床試驗與研究計畫,CMUH104-REC2-096,彭成元(Peng, Cheng-Yuan),賴學洲(Lai, Hsueh-Chou)、蘇文邦(Wen-Pang Su)、陳昇弘(Chen, Sheng-Hung)、陳景祥,附醫廠商計畫,一項隨機分配、雙盲、安慰劑對照的試驗,用以評估ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) 以及 ABT-333 治療未曾接受治療以及曾接受治療,患有非肝硬化、慢性 C型肝炎病毒 (HCV) 基因亞型1b感染之亞洲成人的療效及安全性,$9847954,2017.1.1 ~ 2017.12.31
26﹒ 臨床試驗與研究計畫,CMUH104-REC1-086,彭成元(Peng, Cheng-Yuan),陳昇弘(Chen, Sheng-Hung)、陳景祥、賴學洲(Lai, Hsueh-Chou)、蘇文邦(Wen-Pang Su),附醫廠商計畫,評估ASC16 (Ravidasvir)合併由Ritonavir強化之ASC08 (Danoprevir)及Ribavirin用於未曾接受治療且無肝硬化的台灣慢性C型肝炎基因型第1型病患之療效、安全性及藥物動力學試驗。,$1147645,2017.1.1 ~ 2017.12.31
27﹒ 個別型,MOST 104-2628-B-039 -001 -MY4,馬文隆(Wen-Lung Ma),賴學洲(Hsueh-Chou Lai)、彭成元(Cheng-Yuan Peng),科技部,肝癌治療的轉譯研究:從男性激素受體訊息基礎研究到發展具潛力臨床治療之評估,$1479000,2016.8.1 ~ 2017.7.31
28﹒ 個別型,A1041016,周德陽(Der-Yang Cho),趙坤山(Kun-San Chao)、邱昌芳(Chang-Fang Chiu)、蔡銘修(Ming-Hsui Tsai)、彭成元(Cheng-Yuan Peng)、夏德椿(Te-Chun Hsia)、陳自諒(William Tzu-Liang Chen)、洪耀欽(Yao-Ching Hung)、楊美都(Mei-Due Yang)、葉士芃(Su-Peng Yeh)、劉良智(Liu, Liang-Chih)、楊啟瑞(Che-Rei Yang)、柯道維(TAO-WEI KE)、葉聯舜(Lian-Shung Yeh)、梁基安(Ji-An Liang)、詹佳穎(Chia-Ing Jan)、林文元(Wen-Yuan Lin)、林昭君(Chao-Chun Lin)、蔡伯邦(Po-Pang Tsai)、花俊宏(Chun-Hung Hua)、吳博倫(Po-Lun Wu)、謝清昀(Ching-Yun Hsieh)、簡君儒(Chun-Ru Chien)、楊世能(Shih-Neng Yang)、白禮源(Li-Yuan Bai)、謝右文(Yow-Wen Hsieh)、謝淑惠(Shwn-Huey Shieh)、蔡麗雲(Li-Yun Tsai)、廖惠娟(Hui-Chuan Liao),衛福部,105年度醫院癌症診療品質提升計畫-分項2,$11480000,2016.1.1 ~ 2016.12.31
29﹒ 臨床試驗與研究計畫,DMR98-IRB-048,彭成元(Cheng-Yuan Peng),附醫廠商計畫,在曾接受治療之慢性第1基因型C型肝炎病毒感染病患,評估4種不同MK-7009療方與聚乙二醇化干擾素(Pegylated-Interferon)及Ribavirin同時使用之安全性、耐受性與療效的第二期、隨機分組、安慰劑對照之研究。,$2412366,2016.1.1 ~ 2016.12.31
30﹒ 臨床試驗與研究計畫,DMR97-IRB-228,彭成元(Cheng-Yuan Peng),附醫廠商計畫,一項PR104-2002和Sorafenib針對後期肝細胞癌患者的隨機分配、第I/II期、多中心、開放性試驗,$132659,2016.1.1 ~ 2016.12.31
31﹒ 臨床試驗與研究計畫,DMR98-IRB-191,彭成元(Cheng-Yuan Peng),附醫廠商計畫,對曾參加其它MK-7009臨床試驗的慢性C型肝炎病毒感染病患,併用MK-7009、長效干擾素(Pegylated-Interferon Alfa-2a)及Ribavarin的第二期開放型研究。,$606066,2016.1.1 ~ 2016.12.31
32﹒ 臨床試驗與研究計畫,DMR99-IRB-005,彭成元(Cheng-Yuan Peng),附醫廠商計畫,一項隨機分派、雙盲、安慰劑對照試驗,評估C型肝炎患者在標準併用療法的六個月追蹤期間,經口腔黏膜途徑投予低劑量人類干擾素-α的療效與安全性。,$948000,2016.1.1 ~ 2016.12.31
33﹒ 臨床試驗與研究計畫,DMR99-IRB-043,彭成元(Cheng-Yuan Peng),附醫廠商計畫,針對之前未曾接受過核苷治療的慢性B型肝炎病患開始在門診接受核苷治療的觀察性研究,$228000,2016.1.1 ~ 2016.12.31
34﹒ 臨床試驗與研究計畫,DMR99-IRB-179,彭成元(Cheng-Yuan Peng),附醫廠商計畫,一項多中心、隨機分配、開放性、平行分組第 IIB 期試驗,針對未經治療的C 型肝炎基因型第二型及第三型患者,單獨使用DEB025口服劑或併用ribavirin與標準照護(peg-IFNα2a 加上 ribavirin)比較其療效性及安全性,$1460410,2016.1.1 ~ 2016.12.31
35﹒ 臨床試驗與研究計畫,DMR99-IRB-215,彭成元(Cheng-Yuan Peng),附醫廠商計畫,針對未使用過干擾素,且其B型肝炎病毒e抗原呈陽性的慢性B型肝炎病毒感染病患,評估接受聚乙二醇化干擾素Lambda (BMS-914143)單一藥物治療之安全性、療效和藥物動力學的劑量範圍試驗,$5683364,2016.1.1 ~ 2016.12.31
36﹒ 臨床試驗與研究計畫,DMR100-IRB-054,彭成元(Cheng-Yuan Peng),附醫廠商計畫,隨機、雙盲的安慰劑對照試驗,研究未經治療的第一型基因型 C 型肝炎患者,併用 DEB025 / Alisporivir 與標準療法的療效與安全性,$2839398,2016.1.1 ~ 2016.12.31
37﹒ 臨床試驗與研究計畫,DMR100-IRB-084,彭成元(Cheng-Yuan Peng),附醫廠商計畫,第 III 期、隨機分配、雙盲及安慰劑對照試驗,每日一次 BI 201335 120 mg 治療 24 週,或是 BI 201335 240 mg 治療 12 週,併用長效型干擾素-α 與 ribavirin,用於未曾接受過治療的基因型第 1 型慢性 C 型肝炎感染患者。,$1408139,2016.1.1 ~ 2016.12.31
38﹒ 臨床試驗與研究計畫,DMR100-IRB-065,彭成元(Cheng-Yuan Peng),附醫廠商計畫,一項第四期、隨機、開放式、活性對照之較優性試驗。評估對B肝e抗原呈陽性或陰性、無肝硬化之慢性B型肝炎(CHB)受試者同時使用Tenofovir Disoproxil Fumarate(TDF)及聚乙二醇干擾素Peginterferon α-2a(Pegasys®)之療效及安全性,並與分別使用Tenofovir Disoproxil Fumarate及聚乙二醇干擾素Peginterferon α-2a之48週單一藥物療法進行比較。,$2142071,2016.1.1 ~ 2016.12.31
39﹒ 臨床試驗與研究計畫,DMR100-IRB-150,彭成元(Cheng-Yuan Peng),附醫廠商計畫,第III期、開放性試驗,每日一次BI 201335 240 mg治療24週,倂用長效型干擾素-α (PegIFN)與ribavirin (RBV),用於曾接受PegIFN / RBV治療失敗的基因型第1型慢性C型肝炎感染患者。,$216981,2016.1.1 ~ 2016.12.31
40﹒ 臨床試驗與研究計畫,DMR100-IRB-149,彭成元(Cheng-Yuan Peng),附醫廠商計畫,研究感染C型肝炎患者的IL28B與ITPA基因型盛行率之國際性流行病學試驗,$594851,2016.1.1 ~ 2016.12.31
41﹒ 臨床試驗與研究計畫,DMR100-IRB-162,彭成元(Cheng-Yuan Peng),附醫廠商計畫,針對先前經長效干擾素與Ribavirin治療失敗之第1基因型慢性C型肝炎亞太地區受試者,評估合併使用Boceprevir、Peginterferon與Ribavirin的安全性與療效。,$2640041,2016.1.1 ~ 2016.12.31
42﹒ 臨床試驗與研究計畫,DMR101-IRB1-027,彭成元(Cheng-Yuan Peng),附醫廠商計畫,一項評估IL28B基因型與慢性C型肝炎疾病特徵及病患族群關聯性之國際性多中心研究,$156960,2016.1.1 ~ 2016.12.31
43﹒ 臨床試驗與研究計畫,DMR101-IRB1-028,彭成元(Cheng-Yuan Peng),附醫廠商計畫,評估以長效型干擾素為主的雙重和三重合併療法於治療慢性C型肝炎之應用與影響之非介入性世代研究,$444563,2016.1.1 ~ 2016.12.31
44﹒ 臨床試驗與研究計畫,DMR101-IRB2-074,彭成元(Cheng-Yuan Peng),附醫廠商計畫,一項多中心、3年追蹤研究評估已接受Alisporivir治療的慢性C型肝炎病患,其持續病毒反應之持久性。,$679725,2016.1.1 ~ 2016.12.31
45﹒ 臨床試驗與研究計畫,DMR101-IRB2-075,彭成元(Cheng-Yuan Peng),附醫廠商計畫,一項多中心、3年追蹤研究評估慢性C型肝炎病患在諾華Alisporivir研究中未達持續病毒反應之病毒活性。,$78678,2016.1.1 ~ 2016.12.31
46﹒ 臨床試驗與研究計畫,DMR101-IRB2-054,彭成元(Cheng-Yuan Peng),附醫廠商計畫,評估P1101併用Ribavirin對於未接受治療之感染C型肝炎病毒基因型第2型患者的抗病毒活性與安全性之開放性、隨機分配、有效藥對照的臨床試驗。,$839050,2016.1.1 ~ 2016.12.31
47﹒ 臨床試驗與研究計畫,DMR101-IRB2-132,彭成元(Cheng-Yuan Peng),附醫廠商計畫,針對Asunaprevir與Daclatasvir (DUAL)使用於對Peginterferon α與Ribavirin (P/R)無反應/有部分反應、對P/R不耐受/不合格以及未曾接受治療, 且感染慢性C型肝炎基因型1b的受試者所進行的一項第3期試驗,$5792244,2016.1.1 ~ 2016.12.31
48﹒ 臨床試驗與研究計畫,DMR101-IRB1-205,彭成元(Cheng-Yuan Peng),附醫廠商計畫,一項評估慢性C型肝炎受試者重新接受聚乙二醇化干擾素α-2a、Ribavirin及BMS-790052 (併用或不併用BMS-650032)治療的開放性試驗。,$1103812,2016.1.1 ~ 2016.12.31
49﹒ 臨床試驗與研究計畫,DMR101-IRB1-242,彭成元(Cheng-Yuan Peng),附醫廠商計畫,一項針對亞洲第1型基因型之慢性C型肝炎病毒感染受試者的第Ib期、隨機分配、雙盲、安慰劑對照試驗,以確認採不同劑量及劑量療程給予重複劑量之JNJ-47910382的安全性、耐受性、藥物動力學及抗病毒活性。,$246158,2016.1.1 ~ 2016.12.31
50﹒ 臨床試驗與研究計畫,DMR101-IRB2-254,彭成元(Cheng-Yuan Peng),附醫廠商計畫,評估由Ritonavir所推動之Danoprevir藥物合併Peginterferon alfa-2a及Ribavirin用於未曾接受治療的慢性C型肝炎第一基因型,且有或無代償性肝硬化的亞洲人病患之安全性、耐受性、藥物動力學及抗病毒活性,$835110,2016.1.1 ~ 2016.12.31
51﹒ 臨床試驗與研究計畫,DMR101-IRB1-278,彭成元(Cheng-Yuan Peng),附醫廠商計畫,一項多中心、開放標籤研究,評估PEG-Intron (派樂能) 與PEGASYS (珮格西施)相比,對於B型肝炎E抗原陽性(HbeAg (+))及B型肝炎E抗原陰性(HbeAg (-))的慢性B型肝炎患者的安全性和有效性,$2482359,2016.1.1 ~ 2016.12.31
52﹒ 臨床試驗與研究計畫,DMR101-IRB1-281,彭成元(Cheng-Yuan Peng),附醫廠商計畫,一項第3期、隨機、雙盲、區域性、多國之研究,針對未曾接受治療的基因型第1型與第4型慢性C型肝炎病患,評估使用Daclatasvir併用長效型干擾素Alfa -2a (pegIFN Alfa -2a)以及Ribavirin之療效,$2282820,2016.1.1 ~ 2016.12.31
53﹒ 臨床試驗與研究計畫,DMR101-IRB1-307,彭成元(Cheng-Yuan Peng),附醫廠商計畫,評估P1101併用Ribavirin對於未接受治療之感染C型肝炎病毒基因型第1型患者的抗病毒活性、安全性與藥物動力學之開放性、隨機分配、有效藥對照的臨床試驗(計劃書編號:A11-201),$157558,2016.1.1 ~ 2016.12.31
54﹒ 臨床試驗與研究計畫,DMR101-IRB1-121,彭成元(Cheng-Yuan Peng),附醫廠商計畫,評估P1101對於未接受干擾素治療之感染慢性B型肝炎病毒患者的抗病毒活性、安全性與藥物動力學之開放性、隨機分配、有效藥對照、劑量探索的臨床I/II期試驗(計劃書編號:A12-201),$340242,2016.1.1 ~ 2016.12.31
55﹒ 臨床試驗與研究計畫,CMUH102-REC2-097,彭成元(Cheng-Yuan Peng),附醫廠商計畫,一項第3b期、多中心、開放性試驗,針對韓國與台灣慢性基因型第1型C型肝炎病毒(HCV)感染且未曾接受治療與曾接受治療的受試者,研究Sofosbuvir/Ledipasvir固定劑量配方的療效與安全性,$1211495,2016.1.1 ~ 2016.12.31
56﹒ 臨床試驗與研究計畫,CMUH102-REC2-098,彭成元(Cheng-Yuan Peng),附醫廠商計畫,一項第3b期、多中心、開放性、隨機分配試驗,針對感染慢性C型肝炎基因型1、2、3與6且未曾接受治療的受試者,以及感染慢性C型肝炎基因型2且曾接受治療的受試者,研究Sofosbuvir併用Ribavirin的療效與安全性,$1235421,2016.1.1 ~ 2016.12.31
57﹒ 臨床試驗與研究計畫,CMUH102-REC2-101,彭成元(Cheng-Yuan Peng),附醫廠商計畫,針對曾參與以Asunaprevir (BMS-650032)和/或Daclatasvir (BMS-790052)治療慢性C型肝炎的臨床試驗受試者,進行一項長期追蹤試驗,$1519173,2016.1.1 ~ 2016.12.31
58﹒ 臨床試驗與研究計畫,CMUH102-REC1-089,彭成元(Cheng-Yuan Peng),附醫廠商計畫,一項第三期、隨機、雙盲試驗,評估一日一次25毫克Tenofovir Alafenamide (TAF)療法治療B型肝炎e抗原陽性之慢性B型肝炎時的安全性及療效,並與一日一次300毫克Tenofovir Disoproxil Fumarate(TDF)療法進行比較,$1479329,2016.1.1 ~ 2016.12.31
59﹒ 臨床試驗與研究計畫,CMUH103-REC2-028,鄭隆賓(Long-Bin Jeng),陳永芳(Yung-Fang Chen)、彭成元(Cheng-Yuan Peng)、莊伯恒(Po-Heng Chuang)、賴學洲(Hsueh-Chou Lai),附醫廠商計畫,比較ADI PEG 20合併經導管動脈化學藥物栓塞治療(TACE)與單純經動脈化學栓塞治療於無法手術切除肝細胞癌(HCC)患者之隨機、開放式第二期臨床試驗。,$1725499,2016.1.1 ~ 2016.12.31
60﹒ 臨床試驗與研究計畫,CMUH103-REC2-037,彭成元(Cheng-Yuan Peng),賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、陳昇弘(Sheng-Hung Chen)、陳景祥(Ching-Hsiang Chen),附醫廠商計畫,一項daclatasvir/asunaprevir/BMS-791325固定劑量複方(FDC)的第3期試驗,試驗對象為患有基因型第1型之慢性C型肝炎受試者 (UNITY 4),$2655927,2016.1.1 ~ 2016.12.31
61﹒ 臨床試驗與研究計畫,CMUH102-REC1-127,鄭隆賓(Long-Bin Jeng),莊伯恒(Po-Heng Chuang)、陳永芳(Yung-Fang Chen)、彭成元(Cheng-Yuan Peng)、楊宏仁(Horng-Ren Yang),附醫廠商計畫,第三期、安慰劑對照、多國多中心、隨機分配、雙盲試驗,評估K-333 (peretinoin)用於亞洲肝癌完全治癒受試者之療效及安全性,$3978788,2016.1.1 ~ 2016.12.31
62﹒ 臨床試驗與研究計畫,CMUH103-REC2-041,彭成元(Cheng-Yuan Peng),蘇文邦(Wen-Pang Su)、陳昇弘(Sheng-Hung Chen)、陳景祥(Ching-Hsiang Chen),附醫廠商計畫,一項隨機分配的第三期臨床試驗,研究未曾接受治療的慢性C型肝炎病毒基因第一、四、五、六型感染之受試者使用MK-5172/MK-8742併用療法的療效與安全性。,$1811788,2016.1.1 ~ 2016.12.31
63﹒ 臨床試驗與研究計畫,CMUH103-REC2-042,彭成元(Cheng-Yuan Peng),賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、陳昇弘(Sheng-Hung Chen)、陳景祥(Ching-Hsiang Chen)、黃介良(Chieh-Liang Huang),附醫廠商計畫,一項開放標示的第三期臨床試驗,研究先前未曾接受治療,且目前正接受鴉片類藥物替代療法的慢性C型肝炎病毒基因第一、四、五、六型感染受試者使用 MK-5172/MK-8742併用療法的療效與安全性,$1178897,2016.1.1 ~ 2016.12.31
64﹒ 臨床試驗與研究計畫,CMUH103-REC1-037,彭成元(Cheng-Yuan Peng),陳景祥(Ching-Hsiang Chen)、陳昇弘(Sheng-Hung Chen)、賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su),附醫廠商計畫,利用JKB-122評估對於經干擾素(長效型或短效型)或干擾素和Ribavirin組合治療沒有反應的C型肝炎病毒陽性患者之肝臟功能 (丙胺酸轉胺酶ALT以及天門冬胺酸轉胺酶AST)的第二期,隨機、多劑量、雙盲、安慰劑控制的臨床試驗,$734728,2016.1.1 ~ 2016.12.31
65﹒ 臨床試驗與研究計畫,CMUH103-REC1-061,彭成元(Cheng-Yuan Peng),蘇文邦(Wen-Pang Su)、陳昇弘(Sheng-Hung Chen)、陳景祥(Ching-Hsiang Chen),附醫廠商計畫,一項隨機分配的第三期臨床試驗,研究先前接受聚乙二醇干擾素與雷巴威林(P/R)治療失敗的慢性C型肝炎病毒基因第一、四、五、六型感染之受試者使用MK-5172/MK-8742併用療法的療效與安全性。,$4302340,2016.1.1 ~ 2016.12.31
66﹒ 臨床試驗與研究計畫,CMUH103-REC2-051,彭成元(Cheng-Yuan Peng),蘇文邦(Wen-Pang Su)、陳昇弘(Sheng-Hung Chen),附醫廠商計畫,一項針對曾在臨床試驗中以聚乙二醇化干擾素Lambda-1a (BMS-914143)治療慢性C型肝炎的受試者所進行之長期追蹤試驗,$20000,2016.1.1 ~ 2016.12.31
67﹒ 臨床試驗與研究計畫,CMUH103-REC1-060,彭成元(Cheng-Yuan Peng),賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、陳昇弘(Sheng-Hung Chen)、莊伯恒(Po-Heng Chuang)、陳景祥(Ching-Hsiang Chen),附醫廠商計畫,一項針對使用ThermoDox® (易溶性熱敏感微脂體Lyso-Thermosensitive Liposomal Doxorubicin-LTLD)治療以標準化射頻燒灼術(RFA)治療時間≥45分鐘處理≥3公分至≤7公分單一病灶之肝細胞癌(HCC)的第3期、隨機分配、雙盲、虛擬藥物對照試驗,$620285,2016.1.1 ~ 2016.12.31
68﹒ 臨床試驗與研究計畫,CMUH103-REC2-126,彭成元(Cheng-Yuan Peng),賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、陳昇弘(Sheng-Hung Chen)、陳景祥(Ching-Hsiang Chen),附醫廠商計畫,於亞太地區,針對未曾接受治療且感染基因型第一、四、六型慢性C型肝炎病毒之受試者,評估使用MK-5172/MK-8742併用療法的療效與安全性之隨機分配的第三期臨床試驗,$2649885,2016.1.1 ~ 2016.12.31
69﹒ 臨床試驗與研究計畫,CMUH104-REC2-028,彭成元(Cheng-Yuan Peng),賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、陳景祥(Ching-Hsiang Chen)、陳昇弘(Sheng-Hung Chen),附醫廠商計畫,一項第IIB-III期、開放性、隨機分配的比較試驗,針對亞太地區中罹患慢性B型肝炎的HBeAg陰性成人患者,評估停止核苷(酸)類似物治療後,ABX203維持B型肝炎疾病控制的療效,$1973816,2016.1.1 ~ 2016.12.31
70﹒ 臨床試驗與研究計畫,CMUH104-REC1-002,彭成元(Cheng-Yuan Peng),賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、陳昇弘(Sheng-Hung Chen)、陳景祥(Ching-Hsiang Chen),附醫廠商計畫,針對接受直接抗病毒藥物的B型肝炎病毒病患,找出新的反應決定因素的一項前瞻性生物標記試驗。,$731016,2016.1.1 ~ 2016.12.31
71﹒ 臨床試驗與研究計畫,CMUH104-REC2-026,彭成元(Cheng-Yuan Peng),賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、陳昇弘(Sheng-Hung Chen)、陳景祥(Ching-Hsiang Chen),附醫廠商計畫,一項隨機分配、開放性、多中心試驗評估 ABT-493 與 ABT-530 併用與未併用 RBV 對於感染慢性C型肝炎(HCV)基因型 2 或基因型 3 患者的療效、安全性以及藥物代謝動力學,$119581,2016.1.1 ~ 2016.12.31
72﹒ 臨床試驗與研究計畫,CMUH104-REC2-023,彭成元(Cheng-Yuan Peng),賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、陳昇弘(Sheng-Hung Chen),附醫廠商計畫,一項長期追蹤研究,評估先前臨床試驗中已接受MK-5172治療之慢性C型肝炎受試者,其持續病毒反應和/或病毒抗藥性模式,$1009499,2016.1.1 ~ 2016.12.31
73﹒ 臨床試驗與研究計畫,CMUH104-REC1-018,彭成元(Cheng-Yuan Peng),賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、陳昇弘(Sheng-Hung Chen)、陳景祥(Ching-Hsiang Chen),附醫廠商計畫,一項橫斷生物標記試驗,針對以干擾素治療成功並認定為長期反應者的B型肝炎病毒感染病患,找出新的反應決定因子。,$782378,2016.1.1 ~ 2016.12.31
74﹒ 臨床試驗與研究計畫,CMUH104-REC2-096,彭成元(Cheng-Yuan Peng),賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、陳昇弘(Sheng-Hung Chen)、陳景祥(Ching-Hsiang Chen),附醫廠商計畫,一項隨機分配、雙盲、安慰劑對照的試驗,用以評估ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) 以及 ABT-333 治療未曾接受治療以及曾接受治療,患有非肝硬化、慢性 C型肝炎病毒 (HCV) 基因亞型1b感染之亞洲成人的療效及安全性,$1877476,2016.1.1 ~ 2016.12.31
75﹒ 臨床試驗與研究計畫,CMUH104-REC2-097,彭成元(Cheng-Yuan Peng),賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、陳昇弘(Sheng-Hung Chen)、陳景祥(Ching-Hsiang Chen),附醫廠商計畫,一項開放性試驗,用以評估ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267)以及ABT-333併用Ribavirin (RBV)對於未曾接受治療及曾接受治療、慢性C型肝炎病毒(HCV)基因亞型1b感染且有代償性肝硬化之亞洲成人的安全性及療效,$645382,2016.1.1 ~ 2016.12.31
76﹒ 臨床試驗與研究計畫,CMUH104-REC2-136,彭成元(Cheng-Yuan Peng),賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、陳昇弘(Sheng-Hung Chen)、陳景祥(Ching-Hsiang Chen),附醫廠商計畫,一項隨機分配、開放性、多國多中心,用以評估ABT-493/ABT-530治療慢性C型肝炎病毒基因型第1型之成人病患之療效與安全性之臨床試驗 (ENDURANCE-1),$1011416,2016.1.1 ~ 2016.12.31
77﹒ 臨床試驗與研究計畫,CMUH104-REC1-086,彭成元(Cheng-Yuan Peng),陳昇弘(Sheng-Hung Chen)、陳景祥(Ching-Hsiang Chen)、賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su),附醫廠商計畫,評估ASC16 (Ravidasvir)合併由Ritonavir強化之ASC08 (Danoprevir)及Ribavirin用於未曾接受治療且無肝硬化的台灣慢性C型肝炎基因型第1型病患之療效、安全性及藥物動力學試驗。,$991339,2016.1.1 ~ 2016.12.31
78﹒ 臨床試驗與研究計畫,CMUH104-REC1-048,陳永芳(Yung-Fang Chen),彭成元(Cheng-Yuan Peng)、賴學洲(Hsueh-Chou Lai)、莊伯恒(Po-Heng Chuang)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao)、 陳景祥、陳政國(Cheng-Kuo Chen)、楊宏仁(Horng-Ren Yang)、陳自諒(William Tzu-Liang Chen)、柯道維(TAO-WEI KE)、王輝明(Hwei-Ming Wang)、廖裕民,附醫廠商計畫,台灣選擇性體內放射療法登錄研究,$12600,2016.1.1 ~ 2016.12.31
79﹒ 臨床試驗與研究計畫,CMUH104-REC2-155,彭成元(Cheng-Yuan Peng),賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、陳景祥(Ching-Hsiang Chen)、陳昇弘(Sheng-Hung Chen),附醫廠商計畫,一項開放性、隨機分配、有效藥對照試驗:證明P1101併用Ribavirin對於未接受治療感染C型肝炎病毒基因型第2型患者之療效不劣於PEG-Intron併用Ribavirin,並比較兩者之安全性與耐受性。,$249587,2016.1.1 ~ 2016.12.31
80﹒ 臨床試驗與研究計畫,CMUH104-REC1-112,彭成元(Cheng-Yuan Peng),賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、陳昇弘(Sheng-Hung Chen)、陳景祥(Ching-Hsiang Chen),附醫廠商計畫,一項隨機分配、雙盲、安慰劑對照、多國多中心,用以評估ABT-493/ABT-530治療慢性C型肝炎病毒基因型第2型之成人病患之療效與安全性之臨床試驗 (ENDURANCE-2),$1531057,2016.1.1 ~ 2016.12.31
81﹒ 臨床試驗與研究計畫,CMUH104-REC2-146,彭成元(Cheng-Yuan Peng),賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、陳昇弘(Sheng-Hung Chen)、陳景祥(Ching-Hsiang Chen),附醫廠商計畫,一項對同時受到第 1 或 2 基因型 C 型肝炎病毒 (HCV) 與 B 型肝炎病毒 (HBV) 慢性感染的受試者,施用 Ledipasvir/Sofosbuvir 固定劑量複方劑 12 週的第 3b 期開放標示研究,$919093,2016.1.1 ~ 2016.12.31
82﹒ 臨床試驗與研究計畫,CMUH105-REC2-042,彭成元(Cheng-Yuan Peng),邱昌芳(Chang-Fang Chiu)、蘇文邦(Wen-Pang Su)、陳昇弘(Sheng-Hung Chen)、陳景祥(Ching-Hsiang Chen)、莊伯恒(Po-Heng Chuang)、賴學洲(Hsueh-Chou Lai),附醫廠商計畫,一項隨機、多中心、第III期試驗,以Nivolumab與Sorafenib對照做為晚期肝癌患者的第一線治療,$556849,2016.1.1 ~ 2016.12.31
83﹒ 臨床試驗與研究計畫,CMUH105-REC2-043,彭成元(Cheng-Yuan Peng),賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、陳昇弘(Sheng-Hung Chen)、陳景祥(Ching-Hsiang Chen),附醫廠商計畫,一項在台灣慢性C型肝炎患者中進行的橫斷面觀察性研究:評估肝炎主治醫師建議治療以及患者接受長效型干擾素與雷巴威林合併療法之意願(INITIATE研究),$256794,2016.1.1 ~ 2016.12.31
84﹒ 臨床試驗與研究計畫,CMUH105-REC1-102,邱昌芳(Chang-Fang Chiu),彭成元(Cheng-Yuan Peng)、賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、莊伯恒(Po-Heng Chuang)、王鴻偉(Hung-Wei Wang)、陳景祥(Ching-Hsiang Chen)、陳昇弘(Sheng-Hung Chen),附醫廠商計畫,針對先前接受全身性治療的晚期肝細胞癌受試者,比較Pembrolizumab (MK-3475)與最佳支持性照護作為第二線療法的一項第三期試驗(KEYNOTE-240),$303112,2016.1.1 ~ 2016.12.31
85﹒ 個別型,MOST 104-2314-B-039-014 -,彭成元(Cheng-Yuan Peng),陳昇弘(Sheng-Hung Chen)、張孜菁(Tzu-Ching Chang)、賴學洲(Hsueh-Chou Lai)、陳德鴻(Te-Hong Chen),科技部,肝臟血管竇內皮細胞微環境對肝臟纖維化逆轉之效應,$800000,2015.8.1 ~ 2016.7.31
86﹒ 個別型,MOST 104-2628-B-039 -001 -MY4,馬文隆(Wen-Lung Ma),賴學洲(Hsueh-Chou Lai)、彭成元(Cheng-Yuan Peng),科技部,肝癌治療的轉譯研究:從男性激素受體訊息基礎研究到發展具潛力臨床治療之評估,$1497000,2015.8.1 ~ 2016.7.31
87﹒ 整合型(召集人、總主持人),A1031024,周德陽(Der-Yang Cho),趙坤山(Kun-San Chao)、邱昌芳(Chang-Fang Chiu)、蔡銘修(Ming-Hsui Tsai)、彭成元(Cheng-Yuan Peng)、夏德椿(Te-Chun Hsia)、陳自諒(William Tzu-Liang Chen)、洪耀欽(Yao-Ching Hung)、方信元(Hsin-Yuan Fang)、楊美都(Mei-Due Yang)、葉士芃(Su-Peng Yeh)、劉良智(Liu, Liang-Chih)、柯道維(TAO-WEI KE)、葉聯舜(Lian-Shung Yeh)、梁基安(Ji-An Liang)、林智一(Tze-Yi Lin)、林文元(Wen-Yuan Lin)、蔡伯邦(Po-Pang Tsai)、謝清昀(Ching-Yun Hsieh)、花俊宏(Chun-Hung Hua)、楊世能(Shih-Neng Yang)、簡君儒(Chun-Ru Chien)、白禮源(Li-Yuan Bai)、謝右文(Yow-Wen Hsieh)、蔡麗雲(Li-Yun Tsai)、廖惠娟(Hui-Chuan Liao),衛福部,104年度醫院癌症診療品質提升計畫,$13860000,2015.1.1 ~ 2015.12.31
88﹒ 個別型,MOST 103-2314-B-039-012-,彭成元(Cheng-Yuan Peng),陳昇弘(Sheng-Hung Chen)、賴學洲(Hsueh-Chou Lai),科技部,和以使用膠原蛋白纖維面積比例評估之有持續病毒學反應之慢性C型肝炎肝臟纖維化逆轉相關之肝臟組織分子標記,$850000,2014.8.1 ~ 2015.7.31
89﹒ 整合型(召集人、總主持人),A1021236,周德陽(Der-Yang Cho),蔡銘修(Ming-Hsui Tsai)、蔡伯邦(Po-Pang Tsai)、彭成元(Cheng-Yuan Peng)、邱昌芳(Chang-Fang Chiu)、謝清昀(Ching-Yun Hsieh)、謝右文(Yow-Wen Hsieh)、葉士芃(Su-Peng Yeh)、花俊宏(Chun-Hung Hua)、楊世能(Shih-Neng Yang)、夏德椿(Te-Chun Hsia)、陳自諒(William Tzu-Liang Chen)、許玲女(Ling-Nu Hsu)、葉聯舜(Lian-Shung Yeh)、林維卿(Wei-Ching Lin)、劉秋松(Chiu-Shong Liu)、梁基安(Ji-An Liang)、陳志毅(Chih-Yi Chen)、洪耀欽(Yao-Ching Hung)、吳錫金(Wu,Hsi-Chin)、謝淑惠(Shwn-Huey Shieh)、柯道維(TAO-WEI KE)、方信元(Hsin-Yuan Fang)、楊美都(Mei-Due Yang)、林文元(Wen-Yuan Lin)、白禮源(Li-Yuan Bai)、范淑貞(Shu-Chen Fan)、劉良智(Liu, Liang-Chih)、簡君儒(Chun-Ru Chien)、林智一(Tze-Yi Lin)、廖惠娟(Hui-Chuan Liao),衛福部,103年醫院癌症診療品質提升計畫,$14400000,2014.1.22 ~ 2014.12.31
90﹒ 整合型(召集人、總主持人),102CANCER,周德陽(Der-Yang Cho),陳志毅(Chih-Yi Chen)、邱昌芳(Chang-Fang Chiu)、蔡銘修(Ming-Hsui Tsai)、彭成元(Cheng-Yuan Peng)、蔡伯邦(Po-Pang Tsai)、謝清昀(Ching-Yun Hsieh)、謝右文(Yow-Wen Hsieh)、葉士芃(Su-Peng Yeh)、花俊宏(Chun-Hung Hua)、楊世能(Shih-Neng Yang)、夏德椿(Te-Chun Hsia)、陳自諒(William Tzu-Liang Chen)、許玲女(Ling-Nu Hsu)、葉聯舜(Lian-Shung Yeh)、何永仁(Yung-Jen Ho)、劉秋松(Chiu-Shong Liu)、梁基安(Ji-An Liang)、洪耀欽(Yao-Ching Hung)、吳錫金(Wu,Hsi-Chin)、謝淑惠(Shwn-Huey Shieh)、柯道維(TAO-WEI KE)、方信元(Hsin-Yuan Fang)、楊美都(Mei-Due Yang)、林文元(Wen-Yuan Lin)、白禮源(Li-Yuan Bai)、葉名焮(Ming-Hsin, Alex, Yeh)、簡君儒(Chun-Ru Chien)、林智一(Tze-Yi Lin)、范淑貞(Shu-Chen Fan),衛福部,102年醫院癌症醫療品質提升計畫,$13132010,2013.1.1 ~ 2013.12.31
91﹒ 個別型,NSC 101-2314-B-039-012,彭成元(Cheng-Yuan Peng),張敏寬(Min-Kuan Chang)、陳昇弘(Sheng-Hung Chen)、賴學洲(Hsueh-Chou Lai),科技部,利用非侵入性模型預測B型或C型肝炎病人之肝臟纖維化分級,$900000,2012.8.1 ~ 2013.7.31
92﹒ 國家型,101CANCER,周德陽(Der-Yang Cho),方信元(Hsin-Yuan Fang)、白禮源(Li-Yuan Bai)、何永仁(Yung-Jen Ho)、李郁芬(Yu-Fen Li)、林文元(Wen-Yuan Lin)、花俊宏(Chun-Hung Hua)、邱昌芳(Chang-Fang Chiu)、柯道維(TAO-WEI KE)、洪耀欽(Yao-Ching Hung)、孫茂峰(SUN, MAO-FENG)、張兆祥(Chang,Chao-Hsiang)、梁基安(Ji-An Liang)、許玲女(Ling-Nu Hsu)、陳自諒(William Tzu-Liang Chen)、陳志毅(Chih-Yi Chen)、陳碧惠(Pi-Hui Chen)、彭成元(Cheng-Yuan Peng)、楊美都(Mei-Due Yang)、葉士芃(Su-Peng Yeh)、葉聯舜(Lian-Shung Yeh)、劉良智(Liu, Liang-Chih)、劉秋松(Chiu-Shong Liu)、蔡伯邦(Po-Pang Tsai)、蔡銘修(Ming-Hsui Tsai)、謝右文(Yow-Wen Hsieh)、謝淑惠(Shwn-Huey Shieh)、林智一(Tze-Yi Lin)、謝清昀(Ching-Yun Hsieh),衛福部,101年醫院癌症醫療品質提升計畫,$14285090,2012.1.1 ~ 2012.12.31
93﹒ 產學合作,09842720,鄭隆賓(Long-Bin Jeng),楊美都(Mei-Due Yang)、彭成元(Cheng-Yuan Peng)、鄭庚申(Ken-Sheng Cheng)、楊宏仁(Horng-Ren Yang)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao)、莊伯恒(Po-Heng Chuang)、賴學洲(Hsueh-Chou Lai)、陳永芳(Yung-Fang Chen),附醫廠商計畫,一項隨機分配、雙盲、多中心的第三期臨床研究,對於患者晚期肝細胞癌之病患,以BRIVANIB或SORAFENIB作為第一線治療之比較(BRISK FL研究)』,$3029343,2011.7.1 ~ 2012.5.31
94﹒ 國家型,1000104CANCER,周德陽(Der-Yang Cho),陳志毅(Chih-Yi Chen)、邱昌芳(Chang-Fang Chiu)、孫茂峰(SUN, MAO-FENG)、蔡銘修(Ming-Hsui Tsai)、陳自諒(William Tzu-Liang Chen)、梁基安(Ji-An Liang)、韓鴻志(Horng-Jyh Harn)、楊美都(Mei-Due Yang)、方信元(Hsin-Yuan Fang)、葉士芃(Su-Peng Yeh)、劉秋松(Chiu-Shong Liu)、張兆祥(Chang,Chao-Hsiang)、謝右文(Yow-Wen Hsieh)、羅偉忠(Lo Woei Chung)、林文元(Wen-Yuan Lin)、何永仁(Yung-Jen Ho)、彭成元(Cheng-Yuan Peng)、洪耀欽(Yao-Ching Hung)、葉聯舜(Lian-Shung Yeh)、劉良智(Liu, Liang-Chih)、蔡伯邦(Po-Pang Tsai)、花俊宏(Chun-Hung Hua)、柯道維(TAO-WEI KE)、白禮源(Li-Yuan Bai)、謝清昀(Ching-Yun Hsieh)、許玲女(Ling-Nu Hsu)、謝淑惠(Shwn-Huey Shieh)、陳碧惠(Pi-Hui Chen)、李郁芬(Yu-Fen Li)、何文照(Wen-Chao Ho),衛福部,100年至101年醫院癌症醫療品質提昇計劃(100年度),$13640000,2011.1.4 ~ 2011.12.31
95﹒ 產學合作,099427E2,彭成元,賴學洲(Hsueh-Chou Lai)、蘇文邦、高榮達(Jung-Ta Kao),附醫廠商計畫,針對未使用過干擾素,且其B型肝炎病毒e抗原呈陽性的慢性B型肝炎病毒感染病患,評估接受聚乙二醇化干擾素Lambda (BMS-914143)單一藥物治療之安全性、療效和藥物動力學的劑量範圍試驗,$2075875,2010.11.19 ~ 2011.11.18
96﹒ 產學合作,09842721,鄭隆賓(Long-Bin Jeng),楊美都(Mei-Due Yang)、彭成元(Cheng-Yuan Peng)、鄭庚申(Ken-Sheng Cheng)、楊宏仁(Horng-Ren Yang)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao)、莊伯恒(Po-Heng Chuang)、賴學洲(Hsueh-Chou Lai)、陳永芳(Yung-Fang Chen),附醫廠商計畫,一項隨機分配、雙盲、多中心的第三期臨床研究,對於患者有晚期肝細胞癌(HCC)但對SORAFENIB治療失敗或不耐受的受試者,施以BRIVANIB加上最佳支持行照顧(BSC)與安慰劑加上最佳支持性照護(BSC)之比較:BRISK PS,$1471185,2010.9.1 ~ 2011.8.31
97﹒ 產學合作,099427C4,彭成元(Cheng-Yuan Peng),彭成元(Cheng-Yuan Peng)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao),附醫廠商計畫,一項多中心、隨機分配、開放性、平行分組第IIB期試驗,針對未經治療的C型肝炎基因型第二型及第三型患者,單獨使用DEB025口服劑或併用ribavirin與標準照護(peg-IFN α 2a 加上ribavirin)比較其療效性及安全性,$1327350,2010.9.17 ~ 2011.9.16
98﹒ 個別型,DMR-100-015,彭成元(Cheng-Yuan Peng),施朝仁(Chao-Jen Shih),附醫院內計畫,B型肝炎病毒變異株在e抗原陽性慢性B型肝炎病患接受長效型干擾素治療過程中病毒量竄升所扮演角色之研究,$250000,2010.8.1 ~ 2011.7.31
99﹒ 個別型,DMR-100-017,陳昇弘(Sheng-Hung Chen),彭成元(Cheng-Yuan Peng),附醫院內計畫,聲脈衝輻射力成像(ARFI)技術於預測B型和C型肝炎病毒感染病患肝臟纖維化之臨床運用,$200000,2010.8.1 ~ 2011.7.31
100﹒ 產學合作,09842720,鄭隆賓(Long-Bin Jeng),楊美都(Mei-Due Yang)、彭成元(Cheng-Yuan Peng)、鄭庚申(Ken-Sheng Cheng)、楊宏仁(Horng-Ren Yang)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao)、莊伯恒(Po-Heng Chuang)、賴學洲(Hsueh-Chou Lai)、陳永芳(Yung-Fang Chen),附醫廠商計畫,一項隨機分配、雙盲、多中心的第三期臨床研究,對於患者晚期肝細胞癌之病患,以BRIVANIB或SORAFENIB作為第一線治療之比較(BRISK FL研究)』,$3029343,2010.7.1 ~ 2011.6.30
101﹒ 產學合作,099427B1,鄭隆賓(Long-Bin Jeng),楊宏仁(Horng-Ren Yang)、楊美都(Mei-Due Yang)、莊伯恒(Po-Heng Chuang)、彭成元(Cheng-Yuan Peng)、蘇文邦(Wen-Pang Su)、賴學洲(Hsueh-Chou Lai)、鄭庚申(Ken-Sheng Cheng)、高榮達(Jung-Ta Kao)、陳永芳(Yung-Fang Chen)、陳德鴻(Te-Hong Chen),附醫廠商計畫,一項臨床第四期、單組、開放性試驗,評估sorafenib(Nexavar蕾莎瓦R)使用於晚期肝細胞腫瘤(肝癌)患者,$3933108,2010.6.30 ~ 2011.6.29
102﹒ 產學合作,M09842760,彭成元,賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao),附醫廠商計畫,一項隨機分派、雙盲、安慰劑對照試驗,評估C型肝炎患者在標準併用療法的六個月追蹤期間,經口腔黏膜途徑投予低劑量人類干擾素-Α的療效與安全,$2215145,2010.4.20 ~ 2011.4.19
103﹒ 產學合作,09842794,彭成元(Cheng-Yuan Peng),賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao),附醫廠商計畫,針對之前未曾接受過核?治療的慢性B型肝炎病患開始在門診接受核?治療的觀察性研究,$466560,2010.3.29 ~ 2011.3.28
104﹒ 國家型,無,周德陽(Der-Yang Cho),陳志毅(Chih-Yi Chen)、林璨(Tsann Lin)、孫茂峰(SUN, MAO-FENG)、邱昌芳(Chang-Fang Chiu)、蔡銘修(Ming-Hsui Tsai)、陳自諒(William Tzu-Liang Chen)、梁基安(Ji-An Liang)、韓鴻志(Horng-Jyh Harn)、楊美都(Mei-Due Yang)、劉秋松(Chiu-Shong Liu)、張兆祥(Chang,Chao-Hsiang)、謝右文(Yow-Wen Hsieh)、廖裕民(Yu-Min Liao)、林文元(Wen-Yuan Lin)、何永仁(Yung-Jen Ho)、彭成元(Cheng-Yuan Peng)、洪耀欽(Yao-Ching Hung)、葉聯舜(Lian-Shung Yeh)、陳芝蓉(Chih-Jung Chen)、蔡伯邦(Po-Pang Tsai)、花俊宏(Chun-Hung Hua)、柯道維(KE TAO-WEI)、丁文謙(Wen-Chien Ting)、謝清昀(Ching-Yun Hsieh)、許玲女(Ling-Nu Hsu)、謝淑惠(Shwn-Huey Shieh)、陳碧惠(Pi-Hui Chen)、龍紀萱(Chi-Hsuan Lung)、李郁芬(Yu-Fen Li)、何文照(Wen-Chao Ho),,行政院衛生署國民健康局99年醫院癌症醫療品質提升補助計劃,$12600000,2010.1.14 ~ 2010.12.31
105﹒ 產學合作,09842753,鄭隆賓(Long-Bin Jeng),楊宏仁(Horng-Ren Yang)、楊美都(Mei-Due Yang)、莊伯恒(Po-Heng Chuang)、彭成元(Cheng-Yuan Peng)、蘇文邦(Wen-Pang Su)、賴學洲(Hsueh-Chou Lai)、鄭庚申(Ken-Sheng Cheng)、高榮達(Jung-Ta Kao)、陳永芳(Yung-Fang Chen),附醫廠商計畫,比較 LINIFANIB(ABT-869)與SPORAFENIB 對晚期肝細胞癌(HCC)病患的療效及耐受性之開放型,隨機,第三期試驗,$504606,2009.12.30 ~ 2010.12.29
106﹒ 產學合作,09842746,彭成元(Cheng-Yuan Peng),賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao),附醫廠商計畫,對曾參加其它MK-7009臨床試驗的慢性C型肝炎病毒感染病患,併用MK-7009、長效干擾素(PEGYLATED-INTERFERON ALFA-2A)及RIBAVIRIN的第二期開放型研究,$606066,2009.10.21 ~ 2010.10.20
107﹒ 產學合作,09842721,鄭隆賓(Long-Bin Jeng),楊美都(Mei-Due Yang)、彭成元(Cheng-Yuan Peng)、鄭庚申(Ken-Sheng Cheng)、楊宏仁(Horng-Ren Yang)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao)、莊伯恒(Po-Heng Chuang)、賴學洲(Hsueh-Chou Lai)、陳永芳(Yung-Fang Chen),附醫廠商計畫,一項隨機分配、雙盲、多中心的第三期臨床研究,對於患者有晚期肝細胞癌(HCC)但對SORAFENIB治療失敗或不耐受的受試者,施以BRIVANIB加上最佳支持行照顧(BSC)與安慰劑加上最佳支持性照護(BSC)之比較:BRISK PS,$1471185,2009.9.1 ~ 2010.8.31
108﹒ 產學合作,09842731,鄭隆賓(Long-Bin Jeng),楊美都(Mei-Due Yang)、彭成元(Cheng-Yuan Peng)、鄭庚申(Ken-Sheng Cheng)、楊宏仁(Horng-Ren Yang)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao)、莊伯恒(Po-Heng Chuang)、賴學洲(Hsueh-Chou Lai)、陳永芳(Yung-Fang Chen),附醫廠商計畫,一項隨機分配、雙盲、多中心的第III期試驗,以BIVANIB相對於安慰劑作為經動脈化療栓塞術(TACE)之輔助療法,用於無法藉由手術切除肝細胞癌之病患:BRISK TA 試驗,$110000,2009.8.13 ~ 2010.8.12
109﹒ 個別型,DMR-99-016,彭成元(Cheng-Yuan Peng),附醫院內計畫,慢性C型肝炎病患周邊血液循環中幹細胞之分離以及其特色探討研究,$150000,2009.8.1 ~ 2010.7.31
110﹒ 產學合作,09842720,鄭隆賓(Long-Bin Jeng),楊美都(Mei-Due Yang)、彭成元(Cheng-Yuan Peng)、鄭庚申(Ken-Sheng Cheng)、楊宏仁(Horng-Ren Yang)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao)、莊伯恒(Po-Heng Chuang)、賴學洲(Hsueh-Chou Lai)、陳永芳(Yung-Fang Chen),附醫廠商計畫,一項隨機分配、雙盲、多中心的第三期臨床研究,對於患者晚期肝細胞癌之病患,以BRIVANIB或SORAFENIB作為第一線治療之比較(BRISK FL研究)』,$3029343,2009.7.1 ~ 2010.6.30
111﹒ 產學合作,09742705,彭成元(Cheng-Yuan Peng),賴學洲(Hsueh-Chou Lai)、蘇文邦(Wen-Pang Su)、高榮達(Jung-Ta Kao),附醫廠商計畫,在曾接受治療之慢性第1基因型C型肝病毒感染病患評估4種不同MK-7009療方與聚乙二醇化干擾素(PEGYLATED-INTERFERON)及RIBAVIRIN同時使用之安全性耐受性與療效的第二期、隨機分組、安慰劑對對照之研究,$1418166,2009.6.1 ~ 2012.12.31
112﹒ 個別型,DMR-98-011,彭成元(Cheng-Yuan Peng),附醫院內計畫,探討慢性C型肝炎第一型病毒感染病患之快速病毒反應與治療療程之關係,$300000,2008.8.1 ~ 2009.7.31
113﹒ 個別型,DMR-97-024,彭成元(Cheng-Yuan Peng),本校(含附醫),慢性C型肝炎病患卵圓形細胞活化及其與甲型胎兒蛋白表達之相關性研究Oval cell activation and its relationship to alpha-fetoprotein expression in patients with chronic hepatitis C,$250000,2007.8.1 ~ 2008.7.31
114﹒ 個別型,NSC95-2314-B-039-037-MY3,蘇冠賓(Kuan-Pin Su),彭成元(Peng,Cheng-Yuan),科技部,不飽和脂肪酸在C型肝炎患者接受干擾素治療誘發的身心副作用之角色探討,$1145000,2006.8.1 ~ 2007.7.31
115﹒ 個別型,DMR-96-105,彭成元(Cheng-Yuan Peng),陳志濱(Chih-Bin Chen),本校(含附醫),血清甲種胎兒蛋白濃度在慢性B型肝炎急性發作併肝失代償病患接受肝安能治療時之意義The significance of serum alpha-fetoprotein levels in patients receiving lamivudine therapy due to acute exacerbation and decompensation of chronic hepatitis B.,$200000,2006.7.1 ~ 2007.6.30